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INTRODUCTION
1
 
Diabetes is the most common endocrine disorder seen in clinical 
practice.  The prevalence of  diabetes  in West  is  between 6-7.6 %. 
India has already become the “diabetes capital” of the world with over 
4 crore affected patients.  Between 1995 and 2025, there is predicted to 
be a 35% increase in the worldwide prevalence of diabetes. The rising 
number of people with diabetes will occur mainly in population of 
developing countries, leading to more than 300 million people with 
diabetes globally by 2025. The disease has tremendous impact on the 
quality of life, and morbidity and mortality occur ue to complications 
that affect the small vessels resulting in retinopathy, nephropathy, 
neuropathy and large vessels resulting in ischemic heart disease and 
stroke. 
 
  Various studies done suggest that thyroid disorders are more                          
common in diabetics (both type I and type II) than in the general 
population,   highest in type I diabetic females  and  lowest  in  type  II  
diabetic males.  
 
  Thyroid dysfunction  is  more  common  in  older  patients.Several 
alterations in  thyroid function are found in DM.The most profound 
changes occur in patients with IDDM. Plasma T4 is normal but plasma 
T3 is diminished.Plasma level of T3  is  elevated  in  DKA or  in 
  
patients  with severely uncontrolled  diabetes.Thyroid peroxidase  
(TPO) antibodies (also  called as anti-microsomal antibodies, AMA) is 
found in large percentage of  IDDM with  elevated TSH  levels and 
when positive in those  with  normal TSH  levels,  indicate  future  
probability  of  the  development  of hypothyroidism in a 
diabetic.Patients with hypothyroidism usually present with vague and 
subtle symptoms like generalized weakness, lethargy, weight gain and 
some present with hoarseness of  voice to ENT surgeon,                       
decreased urine output (nephritic syndrome) to nephrologist, carpal                        
tunnel  syndrome to neurologist, cardiomegaly to  cardiologist, irregular  
and heavy bleeding to    gynecologist. Also  clinically,  it  is   frequently   
difficult  to differentiate  the clinical   features of hypothyroidism from  
that of  diabetes  mellitus  like peripheral  neuropathy    and autonomic   
neuropathy.       
 
 Thyroid  function  tests  are  especially  recommended  in  
patients with  clinical suspicion and /or unexplained changes in 
glycemic control or serum cholesterol. The ability to diagnose and treat 
unsuspected hypothyroidism in these population may greatly enhance 
the quality of life.  
 
 
  
OBJECTIVES 
1. To do the clinical study of hypothyroidism in patients of diabetes 
mellitus, during the study period in Coimbatore Medical College. 
 
2. To study the patients having both endocrine disorders and their 
thyroid function  status,  in relation to  the  age  and  sex,  the  type  
of diabetes , age  at  detection of either condition, the clinical 
features, relation to the lipid profile, body mass index and other co-
morbid conditions. 
 
 
 
  
  
REVIEW OF LITERATURE
2,3,4
 
 
HISTORICAL REVIEW  
 
According  to  Thomson, Greeks  referred  thyroid  gland  as 
bronchocele  (hernia or swelling of the windpipe).  The Latin term 
introduced by Pliny and Juvenal, “tumid gutter” (swollen throat) 
eventually became the French “goitre”, and later  the  English  “goitre”, 
and in America, goiter.  Wharton in 1956  named  the  glands glandulae  
thyroidaeae  (thyroid  glands)  because  of their  anatomical proximity 
to  the thyroid cartilage. Early belief that it enhanced the beauty of 
women , are evidenced by the numerous paintings of the old Dutch, 
German and Italian masters, many of which depict madonnas with an 
enlarged thyroid. 
 
 
 
 The relationship between the thyroid gland and the various body 
functions was studied by experimental thyroidectomy as early as 1827, 
and the concept of an internal secretory function was  formulated by 
King 9 years later.   The injection of a glycerine extract of thyroid to 
relieve myxedema, and finally the feeding of lightly cooked sheep 
thyroid  with  successful  relief  of  disease  completed   the  
background  for  modern knowledge about thyroid function. 
  
  
Meckel  (1806)  was  probably  the  first  person  to  describe  
systematically  the physiological  enlargements  of  the  thyroid  in  
relation  to  adolescence,  menstruation, defloration and pregnancy.   
Hippocrates gave practical association of various features of 
exophthalmic goitre.   Juvenal’s query “who  wonders at a swollen 
throat in the Alps?” indicates that goitre was endemic in that area in the 
first century.  Sir Robert Mecarrision studied the goitre in the foothills 
of Himalayas in 1905 for 30 years.   Early concepts about the etiology 
of goiter were thought to be due to drinking water coursing through 
limestone  deposits  or  drinking  snow  water. 
 
 
 
    
ANATOMY OF THE THYROID GLAND 5,6 
 
              The thyroid gland consists of two symmetrical lobes united in 
front of the second, third and  fourth  tracheal rings by an isthmus of 
gland tissue.It is enclosed by an envelope of pretracheal fascia.  Each 
lateral lobe is pear shaped with a narrow upper pole and is triangular on 
cross section with lateral, medial and posterior surfaces.  The lateral 
surface is overlapped by strap muscles. 
  
  
The medial surface is along the larynx and upper trachea.  The 
posterior surface is in relation to the carotid sheath and parathyroid 
glands. Pyramidal lobe projecting upwards from the isthmus represents 
the glandular tissue at the caudal end of the thyroglossal duct.   Arterial 
supply is by superior and inferior thyroid and thyroidea ima arteries and 
venous drainage is into  the jugular venous system by superior, middle 
and inferior thyroid veins.  Lymphatic drainage is into the deep cervical 
nodes. 
 
 
 
DEVELOPMENT OF THE THYROID GLAND7
 
 
The thyroid gland appears as an epithelial proliferation in the floor 
of the pharynx between the  tuberculum impar and the copula at  a point  
later  indicated by foramen caecum.  It then descends in front of the 
pharyngeal gut as a bilobed diverticulum, while remaining connected to 
the tongue by a narrow canal, the thyroglossal duct, which later 
disappears, to reach its final position in front of the  trachea in the 
seventh week.   The gland begins to function at about the end of the third 
month of intrauterine life, at which time the first follicles containing 
colloid become visible.   Parafollicular or C  cells are derived from the 
ultimobranchial body.  They secrete calcitonin. 
  
  
SYNTHESIS AND SECRETION OF THYROID HORMONES 8  
 
Chemistry 
 
The principal hormones secreted by the thyroid are thyroxine (T4) 
(93%) and tri- iodothyronine (T3) (7%).  Both are iodine containing 
amino acids.  Almost all the T4 is eventually converted to T3 in  the 
tissues. T3  is present  in blood in much smaller quantities and persists 
for a much shorter time than does T4. 
 
Physiologic Anatomy 
 
The  major  constituent  of colloid  present  in the  follicles  is  the  
glycoprotein, thyroglobulin  (Tg) which is bound  to  thyroid  hormones 
and is  synthesised  by  endoplasmic reticulum and  golgi  
apparatus.Each  molecule  of  thyroglobulin  contains  about 70 tyrosine 
amino-acids.When secreted, colloid is ingested by the thyroid cells, the 
peptide bonds are hydrolysed, and free T4 and T3 are discharged into the 
capillaries. 
 
Hormone synthesis: 
 
Iodines ingested are absorbed from  GIT into the blood.  A fifth of 
it is taken up by the thyroid  gland for hormone synthesis.The minimum 
daily iodine intake that will maintain normal thyroid function is 150 µg 
in adults. 
 
  
80 µg 
 
• Iodine pump (iodine trapping) – Na++  & I-  are co-transported 
into the thyroid cell  by secondary active transport. 
• Oxidation of I- to form nascent iodine (Io) or I3- by thyroid 
peroxidase. 
• Organification of Tg – is by binding of oxidised iodine to 
tyrosine molecule attached to Tg forming mono-iodotyrosine 
(MIT) and di-iodotyrosine (DIT).  T3 is formed by condensation 
of MIT with DIT.  A small amount of rT3 is formed by 
condensation of DIT with MIT.  Two DIT molecules condense to 
form T4. 
 
Thyroid Gland
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Conjugates etc. 
T3 
31 µg 
T4 
80 µg 
 
rT3 
38 µg 
 
4 µg 
 
2 µg 
 
27µg 
 
36 µg 
 
17 µg 
 
  
Protein Binding: 
 
Normally, 99.98 % of T4 in plasma is bound, so FT4 is only 2 
ng/dl and 99.8% of T3 is protein bound, so FT3 is only 0.3 ng/dl.  The 
lesser binding of T3 correlates with the fact that T3 has a shorter half 
life than T4 and that its action on the tissues is much more rapid.  The 
major binding protein is TBG (Thyroxine binding globulin); others are 
TBPA (Thyroxine binding prealbumin or Transthyretin) and Albumin.  
TBG levels are increased in pregnancy and with drugs-estrogens, 
methadone, heroin, major tranquilizers and clofibrate; and decreased by 
glucocorticoids, androgens, danazol and asparagine. But free levels of 
T3 and T4 are normal so that the patients are euthyroid.  
 
 
  
  
PHYSIOLOGIC FUNCTONS OF THE THYROID 
HORMONES 
 
1. Increase in the transcription of large numbers of genes by 
binding of T3, T4 to  nuclear receptors. 
2. Increase in cellular metabolic activity by increasing the number 
and activity of mitochondria and increased activity of Na-K-
ATPase 
3. Skeletal growth and closure of epiphyses, development of brain in 
fetus and early postnatal life. 
4. Specific  body  mechanisms  –  Enhanced  carbohydrate  and  fat     
metabolism, increased BMR, increased cardiac output and heart 
rate, increased respiration and gastrointestinal motility,  excitatory 
effects on CNS and increase in the rates of secretion of insulin, 
PTH and glucocorticoid.  Also necessary for normal muscle and 
sexual functions. 
 
  
  
(+) 
(+) 
(-) 
(-) 
FT3 
FT4 
REGULATION OF THYROID SECRETION 
  
 
 
 
 
 
 
Human TSH is a glycoprotein consisting of two subunits α and β.  
TSH-α is identical to the α subunit of LH, FSH and HCG–α and β 
subunit provides the functional specificity. 
 
INVESTIGATIONS FOR THE ASSESSMENT OF THYROID 
STATUS 
10,11 
 
      The clinical features of hypothyroidism develop insidiously over 
months or years; and the diagnosis is often delayed.  However once 
diagnosed, the treatment is simple , yet very effective.  Further,  the  late 
manifestations of hypothyroidism, including cardiac complications  are  
preventable  by  early  detection  and  institution  of  early  treatment. 
Hence hypothyroidism should be suspected in any patient with 
compatible symptoms.  A careful history and a high index of suspicion is 
the key in early diagnosis. 
  
TRH 
TSH 
T3, T4 
Hypothalamus 
Anterior Pituitary 
Thyroid 
  
In suspected primary hypothyroidism, the plasma TSH is the best 
initial diagnostic test.   Plasma  TSH is the first parameter to rise in 
primary hypothyroidism. A normal value excludes primary  
hypothyroidism and a markedly elevated value (more than 15µU/ml)  
is diagnostic of hypothyroidism. A level between  5-15 µU/ml usually 
indicates subclinical hypothyroidism. Plasma total T4 (TT4) or free T4 
(FT4)  is the  next parameter to fall below normal level. A 
combination  of  a  raised  TSH concentration and a low T4 
concentration  has a  great  diagnostic  value  for  primary 
hypothyroidism than serum T3 level. 
 
In central hypothyroidism, serum T4 and T3 are low and serum 
TSH is low or inappropriately normal due to the presence of inactive 
isomers of TSH in the blood. 
 
  
 TSH assays: Second generation assays, namely immuno-
radiometric assays (IRMA) or immuno-enzymometric assays have a 
sensitivity of 0.1-0.2 µU/ml.Third generation assays, namely  immuno-
flourometric  or  immuno-chemiluminometric  assays  have  a 
sensitivity of 0.01-0.02 µU/ml 
 
  
  
Plasma T4: Conventional T4 assays measure total (bound + unbound)  
hormone, which correlates well with free hormone concentration. 
However it  varies with TBG levels.Hence FT4 (free  T4)  is  the  most  
reliable  measure of  clinical  thyroid  status and  is especially 
recommended in 
• Monitoring treatment – thyroid replacement or suppression. 
 
• Hospitalized patients showing symptoms of non thyroidal illnesses. 
 
• Pregnant women suffering from thyroid disorders. 
 
• Patients known to take certain drugs which will interfere with 
total T3 and total T4 results 
 
• When patient’s TFTs do not correlate with clinical history. 
 
 
 
Free T4 index (FT4I): It  is proportional to the actual concentration of 
FT4 in plasma and hence an  indirect  measure of FT4. It is the product 
of total T4 and RT3U (T3 Resin uptake). RT3 U is obtained by an in-
vitro uptake test, in which the serum is enriched with labeled T3 and 
incubated with insoluble resin that binds free hormone.  RT3U is the 
percentage of labeled hormone that is taken up by the resin. 
 
TT3 and FT3: are useful in patients with pituitary disease or after  
 
prolonged suppressed  thyrotroph function due to prior thyrotoxicosis. 
 
  
  
MiscellaneousTests: 
 
1. Thyroid auto-antibodies:  Three types are useful. Anti-
microsomal antibody (AMA), also called anti-thyroperoxidase 
antibodies (anti-TPO) are positive in almost all cases of 
Hashimotto’s disease and ~ 80% of Grave’s disease.   Grave’s 
disease with elevated titers of  AMA should direct surgeon to 
perform a more limited thyroidectomy to avoid future 
hypothyroidism. TSHRAb (TSH receptor antibody) is a predictor 
of relapse of hyperthyroidism in Grave’s disease. 
 
Table 1: Auto-antibodies in Thyroid Disorders (%) 
 
          Group         AMA         TgAb TSHRAb 
General population 8-27 5-20 0 
Autoimmune 
thyroiditis 
90-100 80-90 10-20 
 
Grave’s disease 
50-80 50-70 80-95 
 
Relatives of patients 40-50 40-50 0 
 
IDDM patients 40 40 0 
 
Pregnant women 14 14 0 
 
 
  
  
2. TRH stimulation test : The TSH response to TRH is of less 
importance in the diagnosis  of hypothyroidism, confined only for 
suspected hypothalamic disease 
 
3. RAIU : Radioactive Iodine Uptake Test uses isotopes I123 and 
Tc99 for localizing functional thyroid tissue including ectopic 
thyroid, diagnosing thyroid agenesis in congenital hypothyroidism, 
differential diagnosis of hyperthyroidism (high uptake in  Grave’s  
and  low  in  thyroiditis),   identifying  a  toxic  /  cold  nodule  and 
postoperative / ablation evaluation of thyroid carcinoma.  
 
4. Ultrasound scan of thyroid  : is done using 10 MHz to detect 
nodules and cysts more than 3 mm in diameter.Also used to see 
echogenicity, determination of blood flow and vascularity,  
guidance in FNAC and for aid in treatment – cyst aspiration, 
nodule injection etc. 
 
5. MRI, CT and PET scans : are used to assess the size of large 
goitres those   extending into mediastinum, imaging    of  adjoining 
structures and impingement  of goiter on them,  locating areas  of 
abnormal uptake.MRI  is preferable when metastasis or vascular 
invasion is considered and in those allergic to iodine contrast media. 
 
  
 
6. FNAC   : is used to evaluate both palpable and nonpalpable (under  
USG guidance) nodules. .But it is of limited utility in 
differentiating follicular neoplasms.  Malignancy is diagnosed 
based on capsular invasion. 
  
  
SICK EUTHYROID SYNDROME 12 
 
 
Any acute, severe illness can cause abnormalities of circulating 
TSH or thyroid hormone levels in the absence of underlying thyroid 
disease, making these measurements potentially misleading.  The major 
cause of these hormonal changes is the release of cytokines.   The term 
refers to the global pattern of changes in thyroid physiology that occurs 
during illness due to suppression of pituitary  release of TSH, which is 
either endogenous, because of loss of hypothalamic input or worsened by 
some agents, such as dopamine and glucocorticoids, commonly given to 
such patients.  The changes in thyroid function are a continuum, with the 
abnormalities becoming progressively more severe in accordance with 
the patients clinical condition. 
 
Table 2: Stages of Sick Euthyroid Syndrome 
 
 
 
  Severity of Illness 
    
     FT4 
 
FT3 
 
r T3 
 
TSH 
 
   Stage I (mild) 
 
N 
 
↓ 50% 
 
↑ 2 fold 
 
N 
 
   Stage II (moderate) 
    
 ↑ 
      
↓ 90% 
 
  ↑ Many fold 
 
N 
 
 
   Stage III (Severe) 
     
 
↓ 
 
Almost 
 
undetectable 
 
 
Variable 
 
↓ 
 
  
  
DRUGS THAT CAUSE DECREASED LEVELS OF T4: 
 
Decreased T4 with elevated TSH (True hypothyroidism): 
• Iodine (Amiodarone, radiographic contrast), Lithium  
Decreased   T4 with normal TSH: 
• Androgens – by decreasing TBG levels 
• Frusemide (high dose), Salicylates – by inhibition of T4                 
binding to TBG 
• Phenytoin – multiple mechanisms 
Decreased T4 with decreased TSH: 
• Glucocorticoids, Dopamine – by inhibition of TSH secretion. 
 
Table 3: NORMAL THYROID PROFILE 13
 
 
 
 
 
 
Analyte 
Serum levels in 
 
SI units 
 
Conventional units 
 
T3 
 
0.92 – 2.78 n mol/L 
 
60-181 ng/dl 
 
T4 
 
58-140 n mol/L 
 
4.5-10.9 g/dl 
 
TSH 
 
0.5-4.7 mU/L 
 
0.5-4.7 U/ml 
 
FT3 
 
0.22-6.78 p mol/L 
 
1.4-4.4 pg/ml 
 
FT4 
 
10.3-35 p mol/L 
 
0.8-2.7 ng/dl 
 
FT4I 
 
4.2-13 
 
4.2-13 
 
 
  
  
Table 4:  Interpretation of Thyroid Function Tests:14 
 
 
 
 
TSH normal 
 
T3, T4 
Normal 
 
 
 
TSH high 
 
T3, T4 normal 
 
TSH high 
 
T3, T4 low  or 
T3 normal 
 
T4 low 
 
 
 
TSH  low 
 
T3, T4 low 
 
 
Euthyroid 
 
Subclinical 
 
Hypothyroidism 
 
Primary 
 
Hypothyroidism 
 
Central 
 
Hypothyroidism 
 
 
HYPOTHYROIDISM  
 
Hypothyroidism  is  a  clinical  state  due to  the  decreased  
secretion  of  thyroid hormones  namely  thyroxine  (T4)  and  
triiodothyronine  (T3)  or  very  rarely  due  to  the decreased action of 
these  hormones at tissues.  
Hypothyroidism can be classified into three main categories :15
 
 
 
I Primary Hypothyroidism: Hypothyroidism due to the permanent loss 
or atrophy of thyroid tissue. 
 
II Goitrous Hypothyroidism: Hypothyroidism with compensatory 
thyroid enlargement due to transient or progressive impairment of 
hormone biosynthesis. 
 
 
  
III  Central hypothyroidism:  Hypothyroidism due  to the  insufficient  
stimulation of a normal gland.  It includes: 
a.   Secondary Hypothyroidism is due to defect at pituitary level. 
 
b.   Tertiary Hypothyroidism is due to defect at hypothalamic level. 
 
 
PRIMARY ATROPHIC HYPOTHYROIDISM:  
 
1. Primary  idiopathic  hypothyroidism 
 
2. Post-ablative (iatrogenic): I131, or surgery or therapeutic radiation 
to non-thyroidal malignancy. 
3. Sporadic hypothyroidism (agenesis or dysplasia) 
 
4. Endemic Cretinism (agoitrous form) 
                   
 
GOITROUS HYPOTHYROIDISM 
1. Hashimoto’s  thyroiditis 
2. Riedel’s struma 
3. Endemic Iodine Deficiency  
4. Antithyroid agents 
5. Inherited defects of hormone synthesis 
 
6. Amyloidosis, Cystinosis, Sarcoidosis, Hemochromatosis, 
Scleroderma 
 
 
  
  
CENTRAL HYPOTHYROIDISM 
 
1. Secondary hypothyroidism (Pituitary) 
 
a. Panhypopituitarism (Sheehan’s syndrome, tumors,  infiltrative  
disorders).  
b. Isolated TSH deficiency. 
 
2. Tertiary (hypothalamic) hypothyroidism (idiopathic, traumatic,   
tumors, infiltrative disorders) 
 
Clinical Manifestations of  Thyroid HormoneDeficiency
16,17,18
 
                     The clinical features of hypothyroidism are due to the 
direct result of under or absent exposure of end organs to the action of 
thyroid hormones viz., T3 and T4.Almost all the cells in the body have 
thyroid hormone receptors in their cytosol and  respond to thyroid 
hormones to a greater or lesser degree.    
                   Skin and Appendages: Skin is  often dry and coarse due 
to the reduced  secretion  of sweat and sebum. In some cases it may 
resemble icthyosis. It may show faint yellow tint due to 
hypercarotenaemia. Nails are brittle with  vertical and transverse 
fissures and grow slowly.Hair may be lost from the lateral 1/3 of the 
eyebrow (madarosis). In severe cases (myxoedema),                      
periorbital  puffiness and non-pitting boggy edema  is seen; especially 
in feet and legs and even in hands.These features are  due to the  
  
accumulation of  mucopolysaccharides hydrophilic  hyaluronic  acid  and  
chondroitin sulfate,   in the  ground  substance  of the dermis and other 
tissues. 
                     
  Respiratory  System:  Pleural  effusions  are  minimal  and  
asymptomatic, and may accompany other serious effusions in 
myxoedema.Lung volumes are  usually  normal; but maximal breathing 
capacity and diffusing capacity are  reduced.   
                   
Gastrointestinal System: Mucosal oedema of the gastrointestinal 
tract leads to  the  poor absorption of nutrients.  Appetite is also reduced.  
But there is modest gain in the  weight due to fluid retention.  However, 
true obesity is not a feature of  hypothyroidism.               
               
Nervous  system:  Thyroid  hormone  is  essential  for  the  
development  of  the central nervous system. If the deficiency is not 
corrected in the early postnatal life, the damage is 
irreversible.Deficiency of thyroid hormone beginning in adult life             
causes less severe nervous system manifestations, which usually 
respond to treatment with thyroid hormone.All intellectual functions, 
including speech are  slowed.Lethargy  and  somnolence  are prominent.  
         
  
    Muscular System: Delayed contraction or relaxation of skeletal 
muscle is the hallmark of hypothyroidism and is the basis of hung-up 
tendon jerks.Cretinism in association with these muscle abnormalities is 
known as Kocher-Debre- Semelaigne syndrome and myxoedema with 
muscle hypertrophy is known as the Hoffmann syndrome.   
 
            Bones & Calcium metabolism: Deficiency of this hormone in 
the early life leads t o  abnormal delayed development of ossification 
centres leading to epiphyseal  dysgenesis. Impairment of linear growth 
leads to dwarfism. 
 
            Renal system: Total body water is increased and is 
responsible for the generalized edema.Renal blood flow, GFR, tubular 
reabsorption and secretory maxima are reduced.  Urinary volume is 
reduced and is one of the first noticeable parameters to reverse with 
treatment. 
 
 
              Reproductive System: Infantile hypothyroidism, if untreated, 
leads to sexual immaturity and  juvenile  hypothyroidism  causes  a  
delay  in  the  onset  of  puberty,  followed  by anovulatory cycles.The  
only significant  manifestation  in  the  male  is  loss  of  libido  and  
erectile dysfunction.  
  
                   
Table 5: Symptoms of Hypothyroidism
19 
 
 
Symptoms % of cases Symptoms % of cases 
Weakness 99 Constipation 61 
Dry skin 97 Gain in weight 59 
Coarse skin 97 Loss of hair 57 
Lethargy 91 Pallor of lips 57 
Slow speech 91 Dyspnoea 55 
Edema of eyelids 90 Peripheral edema 55 
Sensation of cold 89 Anorexia 45 
Decreased sweating 89 Nervousness 35 
Cold skin 83 Menorrhagia 32 
Thick tongue 82 Palpitation 31 
Edema of face 79 Deafness 30 
Coarseness of hair 76 Precordial pain 25 
Pallor of skin 67   
Memory 
impairment 
66   
 
 
 
  
  
Cardiovascular system :Bradycardia, Diastolic hypertension, 
Small volume pulse,  Pericardial effusion and Cardiomegaly are some of 
the features. ECG  changes  : Sinus  bradycardia,  prolonged  PR  
interval,  low  amplitude complexes, ECG  manifestations of other 
cardiac diseases like IHD etc. 
 
Table 6: Cutaneous manifestations of Hypothyroidism
20 
 
 
 
 
 
 
  
Cutaneous manifestations   Approximate Frequency 
Cold intolerance                   50-95 
Nail abnormality (thin, brittle)                     90 
Thickening and dryness of hair and skin                   80-90 
Edema of hands, face and eyelids                   70-85 
Change in shape of face                    70 
Malar flush                    50 
Non-pitting or dependent edema                    30 
Alopecia (loss or thinning of hair)                  30-40 
Pallor                  25-30 
Yellowish discoloration of skin                  25-50 
Decrease or loss of sweat secretion                  10-70 
  
TREATMENT OF HYPOTHYROIDISM:
22,23
 
 
Historically, hypothyroidism was the first endocrine disorder to 
be treated by supplementation  of  the  deficient  hormone. The most  
widely  used and  preferred preparation is synthetic T4 (Thyroxine 
sodium).  Starting dose is 1.6 µg/kg/day (usually100 µg qd), orally, on 
empty stomach, in the morning. In the elderly and those with  
cardiovascular disease, starting dose i s  12.5 µg to 25µg qd. Plasma 
TSH should be measured after 3-4 months. Dose is adjusted in 12-              
15 µg increments at intervals of 6-8 weeks until plasma TSH is 
normal.Subclinical hypothyroidism is  treated if  symptoms  of  
hypothyroidism, goitre, hypercholesterolemia or positive AMA are there.  
Untreated patients should be monitored annually.                                            
 
Myxoedema  coma
24
  is  life  threatening  and  should  be managed  
with  intensive supportive care and thyroid hormone replacement.  
Management includes respiratory and cardiovascular assistance, 
correction of hyponatremia and  hypoglycemia and treatment of infection 
and hypothermia.Hydrocortisone 200-400 mg/day is recommended.  As 
IV  preparations of thyroid hormones are not marketed in India, give 
400-500 µg of thyroxine  through Ryle’s tube on the first day and               
100 µg/day subsequently.        
  
DIABETES MELLITUS
25,26,27,28 
 
 
 
The term diabetes mellitus describes a metabolic disorder of 
multiple aetiology characterized  by  chronic  hyperglycaemia  with  
disturbances of carbohydrate,  fat  and protein metabolism resulting 
from defects in insulin secretion, insulin action, or both. The effects of 
diabetes mellitus include long-term damage, dysfunction and failure of 
various organs.  Diabetes  mellitus  may  present  with  characteristic  
symptoms  such  as  thirst, polyuria, blurring of vision, and weight loss. 
In its most severe forms, ketoacidosis or a non-ketotic hyperosmolar 
state may develop and lead to stupor, coma and, in absence of effective  
treatment, even death. Often  symptoms are not severe, or may  be  
absent,  and consequently hyperglycaemia sufficient to cause 
pathological and functional changes may be present for a long time 
before the diagnosis is made.The long-term complications of diabetes 
mellitus include retinopathy with potential blindness,nephropathy that  
may lead to renal failure,and/or neuropathy with risk of foot ulcers, 
amputation, Charcot joints, and features of autonomic disturbances  like  
sexual dysfunction.People with diabetes are at increased risk of 
cardiovascular, peripheral vascular and cerebro vascular disease. 
 
  
  
    Several mechanisms are involved in the development of 
diabetes.These include  processes which destroy the beta cells of the 
pancreas with consequent insulin deficiency, and others  that result in 
resistance to insulin action.  
 
Table 7: Values for diagnosis of diabetes mellitus and other 
categories of  hyperglycemia
29,30 
 Plasma Venous Glucose 
concentration,  
               mmol/ l(mg /dl) 
Diabetes Mellitus: 
Fasting                                  
Or 
2-h post glucose load 
or both                                  
 
>7.0 (>126) 
  
>11.1 (>200) 
Impaired Glucose Tolerance 
                    (IGT): 
Fasting  
  
and 
 
2-h post glucose load 
 
 
>6.1(>110) 
<7.0 (<126) 
 
 
>7.8 (>140) and <11.1 (<200)        
Impaired Glucose Glycaemia 
                     (IGG) 
Fasting 
and  
2-h post glucose load      
 
   
 
>6.1 (>110) and 
<7.0 (<126)     
 
<7.8 (<140)            
 
 
 
  
 
Table 8: CLASSIFICATION OF  DIABETES MELLITUS
31,32 
 
Type 1 
 
(beta cell destruction, usually leading to absolute insulin deficiency) 
• Autoimmune 
• Idiopathic 
 
Type 2 
 
(may range from predominantly insulin resistance with relative 
 
insulin deficiency to a predominantly secretory defect with or without  
 
insulin resistance) 
 
Other specific types 
 
 
• Genetic defects of β-cell function(HNF4alpha MODY1, 
glucokinase MODY4   etc) 
 
 
• Genetic defects in insulin action  
 
• Diseases  of the exocrine pancreas 
(Fibrocalculouspancreatopathy,Haemochromatosis ) 
 
• Endocrinopathies 
(Cushing'sSyndrome,Acromegaly,Phaeochromocytoma 
Glucagonoma ,Hyperthyroidism, Somatostatinoma ) 
 
• Drug  or chemical induced 
 
• Infections (Congenital rubella ,Cytomegalovirus ) 
 
• Uncommon forms of immune-mediated diabetes 
  
  
Treatment of Diabetes mellitus 
 
 
Table 9: Oral Antihyperglycemic Agents
33,34 
 
 
     Drug class 
 
    Agents 
Reduction 
in HbA1c 
(%) 
 
  Patients   best  suited 
       For    treatment 
 
 
  Sulfonylureas 
Glyburide 
Glipizide 
Glimepiride 
Glibenclamide 
Gliclazide 
 
 
0.8 to 2.0 
 
Patients with recently 
diagnosed type 2 diabetes 
 
  Meglitinides 
 
Repaglinide 
 
Nateglinide 
 
0.5 to 2.0 
Patients with recently 
diagnosed  type 2 DM who 
have high postprandial 
glucose levels 
 
   Biguanides 
 
Metformin 
 
1.5 to 2.0 
 
Obese patients with
 recently 
diagnosed type 2 diabetes 
 
Thiazolidinediones 
 
Pioglitazone 
 
 Rosiglitazone 
 
 
0.5 to 1.5 
 
Patients who are obese 
or Insulin resistant 
 
Alpha  
glucosidase 
inhibitors 
 
Acarbose 
 
Miglitol 
 
 
0.7 to 1.0 
 
Patients with high 
postprandial  glucose levels 
 
  
  
Table 10:  Types of insulin
35,36 
 
 
 
INSULIN   TYPE 
 
INSULIN 
 
 
PEAK 
(hours) 
 
DURATION 
(hours) 
Rapid  acting analogue 
(clear) 
Lispro 
 
Aspart 
 
0.25 
 
0.5-1.5 
 
2-5 
Fast  acting (clear) Regular 0.5-0.7 1.5-4.0 5-8 
Intermediate-acting 
 
(cloudy) 
NPH 
Lente 
 
1-2 
 
6-12 
 
18-24 
Long-acting (cloudy) Ultralente  
4-6 
 
16-18 
 
20-36 
 
Extended  long-acting 
analogue 
 
Glargine 
 
Detemir 
 
 
2-5 
 
 
5-24 
 
 
18-24 
Premixed (cloudy) 
 
A single vial contains a 
fixed ratio of insulin 
(% rapid or fast acting to 
% intermediate acting 
insulin) 
 
 
30/70, 
50/50, etc. 
 
 
_ 
 
 
_ 
 
 
_ 
 
Complications of Diabetes mellitus: 
 
Short term Complications: 
Hypoglycemia, Diabetic ketoacidosis, 
Hyperglycemic hyperosmolar syndrome. 
 
Long-Term Complications 
 Dyslipidemia,Hypertension ,Cardiovascular Disease ,Vascular  
 Complications, Diabetic Retinopathy, Renal Complications etc. 
 
ONSET 
(hours) 
 
  
HYPOTHYROIDISM AND DIABETES MELLITUS
37 
 
Diabetic patients have a higher prevalence of thyroid disorders 
compared with the normal population. 
Thyroid Disease in Diabetics: 
                        Overall prevalence: 10.8–13.4% 
                        Subclinical Hypothyroidism:5-9% 
                        Clinical Hypothyroidism: 1 – 2%          
         The overall prevalence of hypothyroidism in women with 
diabetes was 8.8%  with  5%  in  those  <60  years  and  21%  in  >60  
years
38
.The  prevalence  of hypothyroidism among people with diabetes 
ranges from 0.2 to 6 % depending on age and sex
39
. Ganz and Kozak, 
at Joslin’s clinic, reviewed the records of 60,703 patients with diabetes 
from 1957 to  1972 and reported 114 (0.19%) cases of 
hypothyroidism
40
.Among these, from October 1957 to September 1965, 
an additional 52 cases of primary hypothyroidism (0.24%) were 
diagnosed among 21,500 new diabetic patients
41
. Hecht and Gerschberg 
reported 9 hypothyroid patients(1.7%) out of 530 patients with diabetes 
who  attended their metabolism clinic
42
. Perros reported a prevalence 
rate of 13.4% for all types of thyroid disease among a population with 
diabetes receiving annual thyroid  screening
43
. Smithson  noted  that  65 
of  the  women with diabetes  also  had   hypothyroidism on screening of 
197 patients
44
. 
  
Feely and Isles reported a 4% prevalence of clinical 
hypothyroidism in diabetics.  They also noted an increased prevalence 
(5%) in women with diabetes who  were older than 60  years
45
.Cross 
sectional studies  have reported a prevalence of hypothyroidism in 12-
24 % of female and 6% of male patients with IDDM as well as in 3-6% 
of NIDDM patients
46,47,48,49 
 
TYPE I DIABETES MELLITUS AND AUTOIMMUNITY
50,51
 
 
 The basis of increased thyroid dysfunction in type I diabetes 
is autoimmunity. Primary  hypothyroidism in most instances is probably 
due to thyroid atrophy resulting from end-stage chronic lymphocytic 
thyroiditis.The prevalence of autoantibodies in  juvenile  diabetics has 
been reported  by different authors to be around 22%, 17% and 8% 
respectively
52,53,54
.The study by Riley et al.,showed 17% of IDDM  to 
be positive for AMA, of which 38% were hypothyroid (including 
subclinical and 1/3rdof which were undiagnosed) and another 5% (total 
43%) of IDDM with AMA positive  became clinically and /or  
biochemically hypothyroid.  
 
 In a study of 278 patients with diabetes mellitus, the 
incidence of goiter was 31.8% and was higher in females than in 
males; and the incidence of AMA and Tg-Ab was 18.5% and 1.8% 
respectively. 
  
           In the study by Umpierrez
55
,   33% patients of type I Diabetes 
had  positive TPO Ab. Hypothyroidism was  most  common in female  
subjects with positive (83%)  as compared with negative (12%) TPO.  
Similarly, the rate of hypothyroidism was higher in male subjects with 
positive (51%) than  with negative (3%) TPO antibodies. 17/18 0f TPO 
positive at the beginning of the study remained positive throughout the 
study period.The mean age of onset of hypothyroidism was earlier in 
those TPO positive and also of onset of diabetes when compared to TPO 
negative subjects. 
 
 
 Patients who were TPO  positive  were  17.91 times  more  
likely  to  develop hypothyroidism.Also, long term follow up is 
necessary because the onset of diabetes usually precedes the diagnosis 
of thyroid dysfunction by about one decade.The prevalence of 
hyperthyroidism (including subclinical) was 1.7% and 0.3% in type I 
and type II diabetics respectively.Screening for AMA in IMD (Immune 
Mediated Type I Diabetes) is strongly advised,  and if negative every 
2-3 years until adulthood.Those positive for AMA should have TFTs 
done annually. 
  
  
Other observations that support the possibility of autoimmune process in 
diabetes mellitus are as follows: 
1. The demonstration of islet-cell antibodies in diabetics 
2. Both thyroiditis and IDDM show a stronger association with  
HLA-B8 when  they accompany other autoimmune disorders, 
including Addison’s disease and pernicious anemia, and with 
HLA-DR3 and  DR4.  The  adult  form  of  polyglandular  
autoimmune  syndrome (type2) is associated with disorders of 
the thyroid, adrenal and pancreas (IDDM).In a  study in  
southern India,  autoimmune  diseases were diagnosed  in  1.68%  
of  persons   with  diabetes  mellitus  (147/15,523). Diabetes 
mellitus was diagnosed in 2.3% of persons with hypothyroidism 
(33/1435) and in 4.35% with thyrotoxicosis (15/345)
56
. 
3. Insulitis or lymphocytic infiltration of the pancreas islets has   
been  found in Type 1 DM 
4. Autoantibodies to endogeneous insulin were found by some     
Investigators 
 
  
  
 The study by Gray R.S, Herd R and Clarke B.F
57  was 
done on diabetics with coexisting Grave’s disease or primary 
hypothyroidism.Those with Grave’s disease developed thyroid 
dysfunction and diabetes at an earlier age, than patients with primary 
hypothyroidism.87% of diabetics with thyroid disease were  female, 
56% required insulin treatment and those requiring insulin, the median 
age at diagnosis of diabetes was 36 years (older than the general  
diabetic population).   Whilst diabetes precedes thyroid disease in 
juvenile onset diabetes, the order is  reversed in late onset diabetes.  
Hypothyroidism was diagnosed later (6.7 + 1.2 years) than 
hyperthyroidism 2.4 + 1.2 years) the diagnosis of diabetes, probably 
explained by the extended natural history of asymptomatic autoimmune 
thyroiditis.Similar correlation was also seen with NIDDM who 
presumably share the same etiology.  Absence of any seasonal 
variations suggest that the pathological processes responsible for the 
development of diabetes and autoimmune thyroid disease in the same 
subject are initiated simultaneously and independently of acute 
environmental influences. 
  
  
In the follow-up study done on 109 young adults with type 1 
diabetes by Vondra  in Prague
58
,  cumulative incidence of antibodies 
(AMA and Tg-Ab) was 51% with predominance of women over men 
(65% versus 38%).  Subgroup I (25%) had both AMA and Tg-Ab 
positive (women predominantly); 30% of these had TSH > 4.5 mIU/L 
and subclinical hypothyroidism developed in all patients within 4 years.  
Subgroup II (26%) had only AMA positive (men and women equally); 
7% only had TSH > 4.5 mIU/L and subclinical hypothyroidism 
developed  in only 11% within 4 years.USG pattern of hypoechoic 
gland was seen in 59% and 25 % respectively in 2 subgroups.  
 
Among a diabetic clinic population of 5000, there were 113 
patients (2.26%) with concurrent clinical thyroid dysfunction (56 
hyperthyroid, 57 hypothyroid – 1.1 % each).71 (62.8%) of these were 
IDDM and diabetes preceded thyroid disease in 85 (75.2%).  96 (85%) 
of these were females – 87.7 % in hypothyroid and 82.1 % in 
hyperthyroid group. Percentage of patients on  insulin  was more in 
hypothyroid group than in hyperthyroid group (77.2 % Vs 48.2 %).  
Diabetes was diagnosed first in 89% of hypothyroid Vs only 64.3% of 
hyperthyroid patients.  Mean age at diagnosis of hypothyroidism was 
later than of hyperthyroidism (54 years Vs 32 years)
59
. 
  
  
STUDIES DONE ON TYPE II DIABETICS 
Thyroid function done in 298 type 2 diabetics showed 38 (12.7%) 
suffered from thyroid  dysfunction  –  10.7%  had  hypothyroidism  
(>2/3rd   sub  clinical)  and  2%  had hyperthyroidism.  In 31 cases 
(10.4%) the diagnosis was performed ‘de novo’.Thyroid disease was 
more prevalent among females and elderly
60
. 
 
In a study done on 908 T2DM and 304 non-diabetics at Amman, 
Jordan, the overall prevalence of thyroid disease in diabetics was found 
to be 12.5% of which 5.9% were known to have  thyroid disease and 
rest (6.6%) were newly diagnosed cases as a direct result of screening.   
The most  common was subclinical hypothyroidism (4.1%). The 
prevalence of thyroid disease was 6.6% in the control group
61
. 
 
 
The Indian study done  at  GND  hospital
62
,  Amritsar,  of 184  
cases  of T2DM showed thyroid disease (TD) present in 78 (40.4%) 
cases (50 males, 28 females), but autoimmune thyroiditis (AT) was 
present in 32 (17.4%) cases (8 males, 24 females). There was positive 
correlation with age of patient in TD group but no correlation was 
found  with complication of  diabetes.There was  no  correlation of age,  
severity or complications in AT group but this finding was significantly 
more in female cases. 
  
 In the study sample of 100 patients with T2DM at Chennai
63
, 
the prevalence of TD was  15%subclinical  hypothyroidism  11%,  
hypothyroidism  1%,  subclinical hyperthyroidism 2% and  
hyperthyroidism 1%.The prevalence is higher than in the general 
population and in females. 
 
 
 In the study of 120 T2DM patients at Hyderabad
64
 , 
hypothyroidism was seen in   32 (27%, 10% being subclinical), of 
which 80% were  females. 70% of patients with hypothyroidism were 
between 40-60 years age.  Only in 1%, hypothyroidism preceded 
T2DM. Only 2% of hypothyroid   patients had significant AMA titres.  
Goiter was noted in 2% of patient. 
 
         
 
POSTPARTUM THYROID DYSFUNCTION IN TYPE I 
DIABETICS
65 
 
 Transient thyroid dysfunction is common in the postpartum 
period in women with T1DM and  warrants routine screening with 
TSH 6-8 weeks after delivery. Glucose control may fluctuate during 
the transient hyperthyroidism followed by hypothyroidism, typical of 
postpartum thyroiditis.  It is important to monitor TFTs in these women 
since approximately 30% will not recover from the hypothyroid state and 
will require thyroxine replacement.  Recurrent thyroiditis with 
subsequent pregnancies is also common. 
  
 In a study by  Hertzel  C Gerstein, PPTD  (postpartum  thyroid  
dysfunction) occurred in  10/40 (25%) – postpartum thyroiditis in 9 
and postpartum Grave’s in 1, during the first 6 months after delivery. 
PPTD occurs in about 5% of women within 1 year of delivery. Risk 
factors for PPTD are family history of thyroid disease/autoimmunity, 
past history of thyroid  disease, female child, goiter, subclinical 
hypothyroidism, positive AMA at term or before delivery and the 
presence of the HLA marker DR4. Thus patients with T1DM may 
benefit from routine screening for thyroid dysfunction at postpartum 
visits and from regular follow-up of any abnormal results. 
 
 
 
INTERACTION BETWEEN THYROID ABNORMALITIES 
AND DIABETES MELLITUS 
  
 Thyroid hormone enhances the absorption, production and 
utilization of glucose. Often latent  diabetes  may be unmasked  by 
hyperthyroidism,  while hypoglycemia is sometimes a manifestation of  
hypothyroidism.Diabetes mellitus appears to influence thyroid function 
a t  several sites,  from hypothalamic  control of TSH,  release of  
T3,production from T4 in  the target tissue etc. The best studied effect  
is the lowering of circulating T3 in diabetics. 
  
  
1)   Thyroid function in diabetes mellitus 
 
      Thyroid hormone metabolism is altered in diabetes and other acute 
and chronic illnesses.  Low T3  is always present in diabetic 
ketoacidosis.  There is a  lowered T3:T4 ratio in the diabetic group.   
Further,  serum T3:T4 ratio shows an inverse correlation with both, 
fasting blood glucose level and HbA1c.Uncontrolled hyperglycemia with 
ketosis lowers T4 and T3 levels and rT3 is elevated.  No change is 
observed in plasma TSH and FT4I is normal.   
2.    Hyperthyroidism and diabetes:
66,67 
 
      IGT was found in 57% of a group of hyperthyroid patients and the 
proportion dropped to 30% when these patients were rendered euthyroid.  
There is 
• Increased intestinal glucose absorption 
 
• Glucose induced insulin release is altered (AMP mediated) 
 
• Marked elevation of fasting plasma glucagon in 30% with 
blunting of arginine induced and protein meal induced glucagon 
responses. 
• Increased activity of gluconeogenic enzymes in liver and kidneys.  
• Role of catecholamines due to hyperadrenergic state  
 
• Resistance to the peripheral action of insulin. 
 
 
  
3.  Hypothyroidism and Diabetes
66,67 
 
The mechanisms of carbohydrate derangements in 
hypothyroidism are unclear. GIT absorption of glucose slows 
down,contributing to the amelioration of  hyperglycemia. Glucose 
turnover is decreased probably due to generalised slowing of the 
metabolic  rate. Hypothyroidism may lead to decrease in insulin 
requirements in diabetic patients. Possibility of hypoadrenalism is 
considered in hypothyroid patients with hypoglycemia. Long standing 
diabetic patients complicated with nephropathy may appear 
pseudomyxedematous with pallor and facial puffiness suggestive of 
hypothyroidism. Derangements  of  lipid  metabolism  in  the  
hypothyroid  state  can  give  rise  to hypercholesterolemia, a well known 
risk factor for cardiovascular morbidity, especially when it is associated 
with hypertension by aggravating the macro and micro-angiopathic 
complications of long standing diabetes mellitus. 
 
4.Hypothalamic-pituitary-thyroid axis in DM 
Diabetic subjects have reduced TRH as well as a blunted pituitary 
TSH  response to TRH. Diabetes mellitus and stress of ketoacidosis 
have an inhibitory effect on the pituitary itself 
  
  
STUDIES DONE TO SHOW THYROID FUNCTION IN  
DIABETICS:
68 
 
 
•   Plasma T4 is normal whereas plasma T3 is diminished and plasma 
level of rT3 is elevated in DKA or in patients with severely 
uncontrolled diabetes. 
•    A negative linear correlation was found between T3 and 
glycosylated  Hb, and a positive  correlation  between  rT3/T3  
and  HbA1c. 
•   In a study of 112 IDDM Patients, T4, T3, rT3 and TBG were 
lower han in control whereas FT4 and FT3 were normal.  T3/rT3 
ratios were stable indicating that peripheral deiodination of T4 is 
preferentially oriented to production of rT3 only during 
ketoacidosis. 
•   Before insulin  treatment, T3 and FT3 were lower and  rT3  
slightly increased. With good metabolic  control  following  insulin  
treatment, T3  and FT3 were slightly increased,  whereas rT3 
slightly decreased. Basal  and  were  not  influenced  by  insulin 
therapy. 
•   T3 level was signifigantly reduced in diabetic patients with vascular 
disease and in female diabetics. 
 
 
  
•    Glucose intolerance was seen in 7/9 patients with subacute 
thyroiditis, which returned to normal after the recovery except 2 
cases with family histories of DM. The results indicated the  
importance of follow-up study of glucose tolerance in subacute 
thyroiditis. 
• In a study of 290 T2DM, abnormal TSH levels were detected 
in  Patients  (31.4%).  TSH  was  repeated  in  these  patients  after  
two  months  of  adequate treatment of diabetes with OAD or 
insulin. TSH concentrations decreased in all but  one  patient  with  
initial  subclinical  hypothyroidism and   ncreased  in  all patients 
with initial subclinical  hyperthyroidism.These changes were 
coupled  with a significant fall of HbA1c levels.In view  of the 
transient changes in TSH secretion,  it  is  suggested that the 
diagnosis of thyroid  dysfunction in T2DM should be delayed 
until improvement of the   metabolic status. 
 
• 59 patients with both clinical evidence of TD and DM were                     
investigated.With development of hyperthyroidism,deterioration 
was seen 63% of insulin treated patients with a 82% increase in 
insulin dosage in  53%.Following  treatment of hyperthyroidism,  
control improved  in 63% with  44% decrease in insulin dosage 
in 59% of them, and insulin was withdrawn in one of them. When 
  
hypothyroidism developed,73% of them had their insulin dosage 
reduced with a high frequency of hypoglycemic  disorders,  
repeated malaise in 55% and coma in 27%. 
 
HYPOTHYROIDISM AND DIABETIC NEPHROPATHY 
 
DM with nephropathy and nephritic syndrome may clinically 
appear myxedematous and pose a differential diagnostic problem.  In 
addition to becoming more insulin   sensitive   and   requiring   less   
insulin,   the   diabetic   patient   who   develops Kimmelstiel-Wilson  
(KW)  disease can  have  physical  findings  similar  to  those  of 
myxoedema – a slowed down appearance, facial puffiness, pallor, and 
pasty countenance. In addition, kidney dysfunction with proteinuria 
tends to affect the results of TFTs to the extent that some of them may 
be misleading or contradictory.  The serum T4 and protein- bound iodine 
levels are low in patients with myxedema and may possibly be low in 
patients  with protein-losing diabetic nephropathy.   Proteinuria results 
in loss of serum  proteins, including TBG.  In patients with myxedema, 
the resin T3 uptake is low, whereas in patients with KW disease, it can be 
high. 
 
  
  
HYPOTHYROIDISM IN DIABETICS TREATED WITH   
SULFONYLUREAS 
 
It  has  been postulated  that  patients  treated  with sulfonylureas  
have  a  higher frequency of hypothyroidism than those treated with 
insulin or diet alone.  The incidence of hypothyroidism was shown to 
increase with the duration of sulfonylurea therapy 
 
These results have been questioned by Burdick and Brice, who in 
their study showed that treatment with sulfonylureas lowers the PBI 
significantly as compared to a matched group treated with diet and insulin 
or diet alone.  This affect is most pronounced with carbutamide, but is not 
seen with tolbutamide in which the amino group is replaced by a methyl 
group.  Furthermore, the doses of sulfonylureas used in the treatment of 
diabetes are too low to have significant anti-thyroid effects. 
 
 
 
 
In the study by Portioli and Rocchi in 200 patients treated with 
tolbutamide and followed for upto 7 years, TFT suggested 
hypothyroidism in 3%, although clinically none of the patients were 
hypothyroid. 
 
 
At the Joslin clinic, a survey revealed that among  9000 diabetic 
patients who had ever received “first generation” sulfonylureas, very few 
only 14 (0.15%) had developed hypothyroidism. 
 
  
METHODOLOGY 
 
 
 
Study Subjects: 
 
 
This study was conducted at Coimbatore Medical college                          
Hospital,Coimbatore from  March 2009 to August 2010.                          
Outpatients attending to the outpatient department and inpatients                    
admitted to the  wards who  were either previously or newly diagnosed  
diabetic were included   in the  study. 
 
 
Inclusion Criteria: 
 
 
Patients of diabetes mellitus either previously or newly diagnosed 
aged more than19 years were included in the study. 
 
Exclusion Criteria: 
 
1.  All patients less than or equal to 19 years of age. 
 
2.  Hypothyroidism arising as a result of thyroid surgery or radiotherapy. 
 
 
 
Study  Design: 
 
1.  Randomly selected diabetic patients were subjected to evaluation for  
 
     thyroid function clinically and biochemically. 
 
  
  
2. Diagnosis of Diabetes mellitus was done as per WHO guidelines. 
 
a. Fasting venous plasma glucose > 126 mg/dl (7.0 mmol/L) 
 
 
b.Two hour venous plasma glucose (post 75 gm glucose) > 200 mg/dl                                                                                                                              
                                                                                                        (11.1 mmol/L) 
 
3. Diagnosis of hypothyroidism was based on values given in table 3 on                                      
page 16. 
 
4. Patients already known to have both diabetes mellitus and 
hypothyroidism were also included. 
 
5.  The  patients  having  both the  conditions  included  in  the  study,  
underwent  other relevant investigations at first visit and on follow-up. 
 
6.  All data regarding patients included was documented as per proforma 
enclosed in the annexure. 
 
7.  Ethical clearance was taken from the institution prior to the 
commencement of the study. 
 
8.  Interpretation of  data  was  done  by  various  statistical  methods. 
  
  
Investigations: 
Routine: 
1.  Hb%, TC, DC, ESR 
 
2.  Urine – Albumin, Sugar and Microscopy 
 
3.  Serum urea and creatinine levels 
 
4.  ECG 
 
5.  Chest X-Ray 
 
6.  Complete Hemogram 
 
7.  Lipid Profile 
 
Diabetes Related: 
 
1. Fasting and two hour postprandial venous plasma glucose levels  
were done by  glucose oxidase method. 
 
Thyroid Related: 
 
1. Serum TSH, T3, T4: by chemiluminescence immunoassay (CLIA) 
method. 
  
  
RESULTS 
One hundred twenty two known or newly detected cases of diabetes 
mellitus aged more  than  19  years  were  selected  randomly  from  the  
outpatients  attending  to  the outpatient department and from  the 
inpatients admitted to the wards in Coimbatore Medical college Hospital  
during the study period. 
Table 11: Distribution of Subjects according to the type of Diabetes 
 
 
Type of Diabetes 
 
Male 
 
Female 
 
Total 
 
Type 2 
 
Type 1 
 
59 
 
19 
 
32 
 
12 
 
91 
 
31 
 
Total 
 
78 
 
44 
 
122 
 
Thus of 122 subjects, 91 were type 2 diabetics (59 males, 32 
females) and 31 were type 1 diabetics (19 males and 12 females). 
 
 
Table 12: Distribution of Subjects as per Age and Sex 
 
Age group 
 
(years) 
Male Female Total 
No. % No. % No. % 
 
20-39 
 
40-59 
 
60-79 
 
Above 80 
 
19 
 
35 
 
22 
 
2 
 
15.6 
 
28.7 
 
18.0 
 
1.6 
 
13 
 
15 
 
15 
 
1 
 
10.6 
 
12.3 
 
12.3 
 
0.9 
 
32 
 
50 
 
37 
 
3 
 
26.2 
 
41.0 
 
30.3 
 
2.5 
 
Total 
 
78 
 
63.9 
 
44 
 
36.1 
 
122 
 
100 
 
CC = 0.064, p = 0.909 (NS) 
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Figure 1: Distribution of subjects as per age and sex 
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Among 122 subjects, 78 (64%) were males and 44 (36%) were 
females; and 50 (41%) patients were in the age group of 40-59 years, 37 
(30.3%) in 60-79 age group, 32 (26.2%) in 20-39 age group, and 
3(2.5%) in above 80 age-group. 
 
Hypothyroidism in Diabetics: 
Table 13: Known and Newly Detected cases of Hypothyroidism                  
In   Diabetics 
 
 
 
Group 
Hypothyroid Patients  
 
 
Total 
 
 
 
% 
 
 
Known 
Newly Detected 
  At First 
    Visit 
On Follow 
up 
Diabetes First 3 12 1 16 13.1 
Hypothyroidism 
First 
 
2 
 
0 
 
0 
 
2 
 
10.5 
Both 
simultaneously 
 
1 
 
0 
 
0 
 
1 
 
5.2 
Total 6 12 1 19 15.6 
F = 1.727; p = 0.182 (NS)      
  
Out of 122 subjects, hypothyroidism and diabetes were observed 
to occur together in 19 patients, of which 8 were clinically 
hypothyroid. All the cases were of primary hypothyroidism. One 
patient was found to have subclinical hyperthyroidism. Thus, the 
prevalence of hypothyroidism (clinical and subclinical) in diabetics was 
15.6 %(19/122).Of 19  hypothyroid  patients,  6  were  known  to  be   
hypothyroid  (5  clinical  and  1 subclinical), 12 were newly detected 
and 1 patient was found to become hypothyroid on follow-up. 
Table 14 Newly Detected cases of Clinical and Subclinical                  
Hypothyroidism in 116 diabetics not known to have                 
hypothyroidism prior to inclusion into the study 
 
 
    Newly Detected cases of  
Number 
 
Percentage 
     Clinical hypothyroidism  
 
             In  Diabetics 
 
              2 
 
        1.7 
   Subclinical Hypothyroidism  
           
             In  Diabetics 
 
             11 
 
        9.5 
 
                  Total 
 
            13 
 
       11.2 
 
 
 
 Thus,  totally  2  new  cases  of  clinical  hypothyroidism  and  
11  new  cases  of subclinical hypothyroidism were detected on 
screening 116 diabetics not known to have hypothyroidism   prior to 
inclusion into the  study. The two cases of clinical  hypothyroidism were 
detected on follow up of 12 months and 16 months respectively. 
  
DM 
Hypothyroid 
Table 15: First Detected condition in patients having both               
Hypothyroidism (clinical  and subclinical) and Diabetes mellitus 
 
 
 
  First Detected No. % 
 
Diabetes Mellitus 
 
Hypothyroidism 
Both 
simultaneously 
 
16 
 
2 
 
1 
 
84.2 
 
10.5 
 
5.3 
Tota  19 100 
                    Chi-Square = 267.791; p = 0.000 (S) 
 
Figure 2: First Detected condition in patients having both 
Hypothyroidism (clinical and subclinical) and Diabetes mellitus 
 
 
 
 
 
 
 
Hence, among the group of subjects having both the conditions, 
diabetes  mellitus was detected first in 84.2%, hypothyroidism in 10.5% 
and both conditions were detected simultaneously  in 5.3% 
  
DM 
Hypothyroid 
Both 
Both 
  
Table 16: First Detected condition and Gap between the two 
conditions in    patients having both Clinical Hypothyroidism and 
Diabetes mellitus 
 
 
 
First Detected 
Type of 
 
Diabetes 
 
No 
 
% 
Gap (years) 
Mean Min. Max. 
 
 
Diabetes mellitus 
T1DM 
 
T2DM 
1 
 
4 
– 
 
– 
9.00 
 
9.62 
– 
 
0.83 
– 
 
22.00 
Total 5 62.5 9.50 0.83 22.00 
 
Clinical Hypothyroidism 
T1DM 
 
T2DM 
1 
 
1 
– 
 
– 
19.50 
 
2.20 
– 
 
– 
– 
 
– 
Total 2 25.0 10.85 2.20 19.50 
 
Both simultaneously 
 
T1DM 
 
T2DM 
 
0 
 
1 
 
– 
 
– 
 
– 
 
0.00 
 
– 
 
– 
 
– 
 
– 
Total 1 12.5 0.00 – – 
Total  8 100 – 0.83 22.00 
 
Figure 3: First detected condition in patients having both                                  
clinical hypothyroidism and diabetes mellitus 
 
 
  DM 
Clinical  
Hypothyroid 
Both 
Both 
DM 
Clinical  
Hypothyroid 
  
Thus, clinical hypothyroidism was seen in 6.5 % (8/122) of 
diabetics. Diabetes was  detected   first  in  5  (62.5%),  clinical  
hypothyroidism  in  2  (25%),  and  both simultaneously in 1 (12.5%) 
patients having both conditions 
Oral Antidiabetic Drugs and Hypothyroidism 
 
Table 17: Use of Oral antidiabetic drugs in Type 2 diabetes with               
different thyroid status 
 
 
                        
                        CC = 0.098; p = 0.643 (NS) 
 
Thus, 94.5% of type 2 diabetics were on oral antidiabetics. 
 
 
Table 18: Duration of use of oral antidiabetic drugs in different            
thyroid status groups 
 
                         
F = 1.727; p = 0.182 (NS) 
 
Thus, the difference in the duration of use of oral antidiabetic drugs in   
different thyroid status was not statistically significant. 
Oral 
Antidiabetic 
Drugs 
Thyroid Status  
Total Normal Subclinical 
Hypothyroid 
Clinical 
Hypothyroid 
 
Used 
(%) 
 
73 
(93.6) 
 
7 
(100) 
 
6 
(100) 
 
86 
(94.5) 
 
No. of type 2 
diabetics 
 
78 
 
7 
 
6 
 
91 
Thyroid Status Mean (years) No. 
Normal 
 
Subclinical Hypothyroidism 
 
Clinical Hypothyroidism 
7.6281 
 
13.7500 
 
6.8080 
78 
 
7 
 
6 
Total 8.1212 91 
  
Analysis of Hypothyroid Patients 
 
Table 19: Distribution of diabetics with coexisting hypothyroidism  
                as per  age-group 
 
   Age-   
  group 
(years) 
    Type 1 Diabetics  
 
Total 
Type 2 Diabetics  
 
Total 
 
Grand 
 
Total 
CH SH CH SH 
M F M F M F M F 
20-39 
 
40-59 
 
> 60 
1 
 
0 
 
0 
1 
 
0 
 
0 
2 
 
0 
 
0 
2 
 
0 
 
0 
6 
 
0 
 
0 
0 
 
2 
 
0 
0 
 
2 
 
2 
0 
 
2 
 
2 
0 
 
0 
 
3 
0 
 
6 
 
7 
6 
 
6 
 
7 
Total 1 1 2 2 6 2 4 4 3 13 19 
 
CC = 0.378 (M), 0.480 (F) 
p = 0.361 (M), 0.147 (F) (NS) 
 
Figure 4: Distribution of type 1 diabetics with coexisting                  
hypothyroidism as per age- group 
  
2 
40-59 >60 
Age Groups (Years) 
No of  
Cases 
0 
1 
0 
Clinical Female 
Clinical Male 
  Sub clinical Male 
  Sub clinical Female 
20-39 
  
Figure 5: Distribution of type 2 diabetics with coexisting 
                 hypothyroidism as per age- group 
 
 
 
 
 
 
 
Thus, all type 1 diabetics with hypothyroidism were in 20-39 years age-
group, whereas type 2 diabetics with hypothyroidism were older, 
maximum in the age-group above 60 years. 
Table 20: Distribution of hypothyroid patients according to the 
type of diabetes mellitus, sex and clinical / subclinical 
hypothyroidism 
 
CC = 0.444 (M), 0.626 (F) 
p = 0.001 (M), 0.000 (F) (S) 
(CH= Clinical Hypothyroidism, SH=Subclinical Hypothyroidism) 
 
Thus, clinical as well as subclinical hypothyroidism was more common 
in females (11.4% Vs 3.8%, and 11.4% Vs 7.7% respectively). 
          Diabetic Patients                    Hypothyroid Patients 
Type of 
 
Diabetes 
No. Male Female 
Male Female SH % CH % SH % CH % 
 
T1DM 
 
19 
 
12 
 
2 
 
10.5 
 
1 
 
5.3 
 
2 
 
16.7 
 
1 
 
8.3 
 
T2DM 
 
59 
 
32 
 
4 
 
6.8 
 
2 
 
3.4 
 
3 
 
9.4 
 
4 
 
12.5 
 
Total 
 
78 
 
44 
 
6 
 
7.7 
 
3 
 
3.8 
 
5 
 
11.4 
 
5 
 
11.4 
Age Groups (Years) 
No of  
Patients 
20-39 40-59 > 69 
Clinical Male 
  Sub clinical Male 
  Sub clinical Female 
  Clinical Female 
0 
1 
2 
3 
  
Table21:Mean  age at  Detection  of Diabetes mellitus and  of Clinical   
Hypothyroidism in patients having both or either of the two 
conditions 
 
 
Mean age (in years) 
 
    At  Detection of 
       Patients of DM with 
 
   Clinical  Hypothyroidism 
     Patients  of   DM   
       with  Normal    
    Thyroid Function 
   
   Diabetes Mellitus 
 
   Type 1 Diabetes 
 
   Type 2 Diabetes 
 
 ClinicalHypothyroidism 
 
40.20 
 
21.56 
 
46.36 
 
43.46 
 
43.18 
  
21.75 
 
50.14 
 
-- 
                                                    
Thus, the mean age at  detection of diabetes mellitus in patients 
having both conditions was  40.2 years which was earlier, compared to 
patients having diabetes mellitus with normal thyroid  function where it 
was 43.18 years (21.56 Vs. 21.75 and  46.36 Vs. 50.14 years among 
type 1 and type 2 diabetics respectively 
  
  
Table 22:Age at detection of Diabetes mellitus and Clinical             
Hypothyroidism in patients having both conditions 
 
Thus, the gap between the onset of two conditions varied from 0.83 to  
22 years in those where diabetes was first to be detected. 
 
  
 
 
Sl. 
 
No. 
            Age(in years) at Onset of   
 
Gap Between 
Two 
(in years) 
 
       Diabetes      
       mellitus 
 
        Clinical 
 
 Hypothyroidism 
 
1 
 
49.1
7 
 
50 
 
0.83 
 
2 
 
             50 
 
63 
 
13 
 
3 
 
             23 
 
32 
 
9 
         
   4 
 
             39 
 
41.6 
6 
 
2.66 
 
5 
 
             50 72 
 
22 
 
6 
 
             42 
 
40 
 
-2 
 
7 
 
20.5 
 
1 
 
           -19.5 
 
8 
 
             48 
 
48 
 
0 
  
Clinical Symptoms and Signs of Hypothyroidism seen in Clinically  
                    
   Hypothyroid  Patients (n = 8) 
 
 
 
                         Table 23: Symptoms of Hypothyroidism 
 
 
Sl. No.          Symptoms Present  in Percentage 
 
1. 
 
Gen. Weakness & lethargy 
 
8 
 
100 
 
2. 
 
  Dryness of skin 
 
6 
 
75 
 
3. 
 
  Cold intolerance 
 
5 
 
62.5 
 
4. 
 
  Decreased sweating 
 
4 
 
50 
 
5. 
 
  Weight gain 
 
4 
 
50 
 
6. 
 
  Paraesthesia 
 
4 
 
50 
 
7. 
 
  Constipation 
 
3 
 
37.5 
 
8. 
 
  Hoarseness of voice 
 
2 
 
25 
 
9. 
 
   Anorexia 
 
2 
 
25 
 
10. 
 
   Decreased hearing 
 
1 
 
12.5 
 
11. 
 
   Menorrhagia 
 
1 
 
12.5 
 
12. 
 
   Palpitations 
 
1 
 
12.5 
 
 
 
 
Thus, generalized weakness and lethargy was the most common 
symptom of hypothyroidism seen in all patients, followed by dryness of 
skin and cold intolerance.                               
  
  
Table 24: Signs of Hypothyroidism 
 
Sl. No. Signs Present  in Percentage 
 
1 
Delayed relaxation of 
ankle jerk 
 
6 
 
75 
 
2 
 
Coarse skin 
 
5 
 
62.5 
 
3 
 
Periorbital puffiness 
 
5 
 
62.5 
 
4 
 
Slow speech 
 
5 
 
62.5 
 
5 
 
Cold skin 
 
4 
 
50 
 
6 
 
Bradycardia 
 
3 
 
37.5 
 
7 
 
Slowness of movements 
 
2 
 
25 
 
8 
 
Facial puffiness 
 
2 
 
25 
 
9 
 
Goitre 
 
2 
 
25 
 
10 
 
Thick tongue 
 
1 
 
12.5 
 
11 
 
Hair loss 
 
1 
 
12.5 
 
12 
 
Limb edema 
 
1 
 
12.5 
 
 
 
Thus, delayed relaxation of ankle jerk was the most common clinical  
 
sign seen in 6 patients, followed by coarse skin and periorbital  
 
puffiness seen in 5 patients. 
  
  
GOITRE AND  THYROID STATUS 
  
 
Table 25: Presence of goitre in different thyroid status groups 
 
 
 
CC= 0.388; p =0.000 (S) 
 
                        Thus, goitre was seen in 4.09% of cases. All the patients 
with goitre had  diffusely enlarged thyroid gland. It was seen more 
common in those hypothyroid (25% of clinical,18.18% of subclinical), 
than normothyroid  patients (0.98%).    
 
  
Thyroid Status Total no. Goitre present % 
 
Normothyroid 
 
Subclinical Hypothyroidism 
Clinical Hypothyroidism  
Subclinical  Hyperthyroidism 
 
102 
 
11 
 
8 
 
1 
 
1 
 
2 
 
2 
 
0 
 
0.98 
 
18.18 
 
25 
 
0 
 
Total 
 
122 
 
5 
 
4.09 
  
Diabetic Complications and Hypothyroidism 
 
Table 26: Frequency of various diabetic complications in relation to 
 
thyroid  status 
 
 
 
Type of 
Diabetes 
 
Thyroid 
 
Status 
Complications (%) 
 
Hypo 
 
DKA 
 
HHS 
 
Neur 
 
Nep 
 
DR 
 
CVA 
 
IHD 
 
PVD 
 
Type 1 
N 
 
SH 
CH 
33.3 
 
25.0 
 
0 
20.8 
 
50.0 
 
50.0 
8.3 
 
50.0 
 
0 
62.5 
 
50.0 
 
50.0 
16.7 
 
25.0 
 
0 
50.0 
 
50.0 
 
50.0 
0 
 
0 
 
0 
16.7 
 
25.0 
 
0 
0 
 
0 
 
0 
 
Type 2 
 
N 
 
SH 
CH 
 
6.4 
 
12.5 
 
20.0 
 
3.8 
 
12.5 
 
0 
 
6.4 
 
0 
 
0 
 
69.2 
 
100 
 
60.0 
 
21.8 
 
87.5 
 
0 
 
47.4 
 
87.5 
 
40.0 
 
5.1 
 
0 
 
0 
 
67.9 
 
100 
 
60.0 
 
2.6 
 
0 
 
0 
 
Contingency 
Coefficient 
 
T1DM 
 
T2DM 
 
0.213 
 
0.128 
 
0.273 
 
0.129 
 
0.397 
 
0.098 
 
0.230 
 
0.198 
 
0.160 
 
0.407 
 
0.174 
 
0.226 
 
- 
 
0.087 
 
0.160 
 
0.201 
 
- 
 
0.06
1  
p value 
 
T1DM 
 
T2DM 
 
0.688 
 
0.471 
 
0.477 
 
0.464 
 
0.122 
 
0.643 
 
0.628 
 
0.157 
 
0.846 
 
0.000 
 
0.809 
 
0.087 
 
- 
 
0.706 
 
0.846 
 
0.146 
 
- 
 
0.84
3  
(CH= Clinical Hypothyroidism, SH=Subclinical Hypothyroidism) 
 
Thus, there was no significant correlation between the thyroid 
status in diabetics and various complications of diabetes mellitus. 
  
  
Table 27: Body Mass Index (BMI), Mean Triglyceride and               
Cholesterol levels in various groups of diabetic patients 
 
 
 
 
 
(CH= Clinical Hypothyroidism,  SH=Subclinical Hypothyroidism,   
 
  N=Normal Thyroid  Status) 
 
Thus, BMI, mean triglyceride and cholesterol levels were more in those 
diabetic patients having  coexisting hypothyroidism, than those diabetic 
patients having normal thyroid status.  But all three were statistically not 
significant. 
  
 
   Groups 
BMI 
        (kg/m 
2
) 
   Triglycerides 
       (mg/dl) 
     Cholesterol 
        (mg/dl) 
 
 T1DM with SH 
 
 T1DM with CH    
 T1DM with N 
 
           19.36 
 
           19.96 
 
           19.09 
 
           195 
 
           225 
 
           192 
 
186 
 
198 
 
166 
 
 T2DM with SH 
 
 T2DM with CH    
 T2D with  N 
 
          25.87 
 
          26.30 
 
          23.05 
 
           176 
 
           235 
 
           174 
 
226 
 
288 
 
198 
    
    F 
 
    p (NS) 
 
           0.973 
 
           0.408 
 
          0.985 
 
          0.402 
 
           0.292 
 
           0.831 
  
DISCUSSION 
 
 
Numerous studies on the prevalence of hypothyroidism (clinical and 
subclinical) in diabetics and relation between them regarding various 
parameters have been done. 
 
Table 28: Subject groups, Parameters studied and Number of  
                 subjects in various studies 
 
 
             Study 
Subject 
 
Group 
 
 
    Parameters      
       Studied 
Subject No. 
 
M 
 
F 
 
T 
Present study DM All 78 44 122 
Michalek AM et al DM Prevalence CH 54 102 156 
Hecht A et al DM Prevalence CH - - 530 
Perros P et al DM First Detected - - 1310 
Smithson MJ et al DM New Cases 122 84 206 
Feely J et al DM Prevalence CH 98 157 255 
Umpierrez GE et al T1 DM Detection Gap 26 32 58 
Gray RS, Herd R et al DM 
 
with HT 
 
Detection Gap 
 
9 
 
89 
 
98 
Gray RS, Borsey DQ et al T1 DM Prevalence HT 294 311 605 
Nobre EL et al T2 DM Prevalence HT - - 77 
Rajan SK et al T2 DM Prevalence HT - - 100 
RamaSwamy M et al T2 DM First Detected 24 96 120 
Zulewski H et al HT  
 
Signs and 
Symptoms of 
Hypothyroidism 
- 50 50 
Tachman ML et al HT 13 64 77 
Murray IP et al HT 22 78 100 
Oddie TH et al HT 12 38 50 
 
(DM=Diabetes mellitus; HT=Hypothyroids; CH=Clinical Hypothyroidism, 
SH=Subclinical Hypothyroidism) 
  
Table 29: Prevalence of hypothyroidism (clinical and subclinical in 
%) in different diabetic groups 
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   Type 1 Diabetics 
 
   Type 2 Diabetics 
 
   Type1DM  Females  
    Type 1DM Males   
   Type2 DM Females    
   Type 2DM Males 
 
19.3 
 
14.3 
25 
 
15.8 
 
21.8 
 
10.2 
 
11.7 
 
- 
 
17 
 
6.1 
 
- 
 
- 
 
- 
 
10.7 
 
- 
 
- 
 
- 
 
- 
 
- 
 
12 
 
- 
 
- 
 
- 
 
- 
 
 
 
Prevalence of hypothyroidism (clinical and subclinical) was 
15.6% in present study, compared to 13.4 % in study by Perros P et al. 
Prevalence of hypothyroidism in type 1 diabetics was 19.3% in the 
present study compared to 11.7% in the study by Gray R S,Borsey DQ 
et al. Hypothyroidism was most common in type 1 diabetic females. 
  
  
Table 30: Prevalence of Clinical Hypothyroidism in Diabetics (%) 
 
 
 Clinical Hypothyroidism in Diabetics 
              
              Total 
      
      Present study 
 
      Michalek A M et al 
 
      Hecht A et al 
 
      Feely J et al 
 
6.5 
 
6.4 
 
1.7 
 
4.0 
 
Clinical Hypothyroidism  in Type2 DM 
                
               Total 
 
      Present study 
  
      Nobre E L et al 
 
      Rajan S K et al 
 
6.6 
 
 
7.2 
 
1.0 
 
 
                          Thus, the prevalence of clinical hypothyroidism in 
diabetics was 6.5% in present study, and ranged from 1.7%  to 6.4% in 
other studies. In type 2 diabetics, the prevalence of clinical 
hypothyroidism was 6.6% in present study, and 7.2% and 1.0%  in other 
studies. 
 
Table 31: First Detected Condition among those with both diabetes  
mellitus and hypothyroidism (clinical and subclinical) 
 
 
 
                       
Thus, in both the studies, diabetes mellitus was detected first in most 
patients with  both conditions. 
 
 
First Detected 
 
 
Present study 
 
Ramaswamy 
 
et al 
 
Diabetes mellitus 
 
Hypothyroidism 
 
Both 
 
78.9 
 
15.8 
 
5.3 
 
99 
 
1 
 
- 
  
Table 32: First detected condition in patients having both Diabetes  
              
             Mellitus and Clinical Hypothyroidism 
 
 
First detected Present study Perros Petal 
 
 Diabetes mellitus 
 
Clinical Hypothyroidism 
 
 Both 
 
62.5 
 
25.0 
 
12.5 
 
89.0 
 
8.8 
 
5.2 
 
Thus,  diabetes  mellitus  was  detected  first  in  most  patients  
having  both  the conditions, whereas both were detected simultaneously 
in 12.5% of cases in the present study. 
 
 
 
Table 33: Gap between Detection of type 1 Diabetes and Clinical  
Hypothyroidism 
 
 
                                   
Mean Gap (in years) 
 
Present 
study 
 
 
Umpierrez GE et al 
 
 
Gray RS, Herd R et al 
 
9.00 
 
8.0 
 
6.7 
 
 
 
Thus, in type 1 diabetics the gap between the detection of two 
was 9 years in present study, was 8 years and 6.7 years, in studies by 
Umpierrez G E et al and Gray RS, Herd R et al respectively. 
  
  
Table 34: Percentage of  New Cases of  Hypothyroidism  detected 
among  Diabetics not known to be  hypothyroid prior to inclusion  
into  the study 
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Subclinical  hypothyroidism 
 
in diabetics 
 
 
9.5 
 
 
4.8 
 
 
2.24 
 
 
30.1 
 
Clinical  hypothyroidism  in 
 
Diabetics 
 
1.7 
 
0.9 
 
1.79 
 
2.7 
 
 
 
Thus, new cases of subclinical hypothyroidism detected  as a 
result of present study was  9.5%, whereas it was 4.8%, 2.24%  and 
30.1% in other studies. New cases of clinical hypothyroidism detected 
as a result of present study was 1.7%, whereas it was 0.9%, 1.79% and 
2.7% in other studies. The high rates of detection of new cases of 
subclinical hypothyroidism in the study by Feely J et al  was probably 
due  to biochemical reassessment of thyroid function tests in those 
having  normal  and  borderline  TSH   levels.  The  higher  prevalence  
of  subclinical hypothyroidism than clinical hypothyroidism in some of   
the studies may be due to the use of sulfonylureas. 
  
  
Table 35:  Frequency of Symptoms of Hypothyroidism (%) 
 
 
 
 
Thus, generalized weakness and lethargy was the most common 
symptom of hypothyroidism  seen in all patients, followed by dryness 
of skin and cold intolerance, seen in majority of cases.  
  
 
 
 
 
Sl. No. 
 
 
 
 
        Symptoms 
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1 
Gen. Weakness & 
lethargy 
 
100 
 
100 
 
99 
 
98 
 
90 
 
2 
 
Dryness of skin 
 
75 
 
76 
 
97 
 
95 
 
79 
 
3 
 
Cold intolerance 
 
62.5 
 
64 
 
89 
 
84 
 
78 
 
4 
 
Decreased sweating 
 
50 
 
54 
 
89 
 
68 
 
68 
 
5 
 
Weight gain 
 
50 
 
54 
 
59 
 
76 
 
63 
 
6 
 
Paraesthesia 
 
50 
 
52 
 
60 
 
56 
 
50 
 
7 
 
Constipation 
 
37.5 
 
48 
 
61 
 
54 
 
47 
 
8 
 
Hoarseness of voice 
 
25 
 
34 
 
52 
 
74 
 
66 
 
9 
 
Anorexia 
 
25 
 
22 
 
45 
 
40 
 
24 
 
10 
 
Decreased hearing 
 
12.5 
 
22 
 
30 
 
40 
 
17 
 
11 
 
Menorrhagia 
 
12.5 
 
12 
 
32 
 
33 
 
15 
 
12 
 
Palpitation 
 
12.5 
 
10 
 
31 
 
23 
 
13 
  
Table 36: Frequency of Signs of Hypothyroidism (%) 
 
 
Thus, delayed relaxation of ankle jerk was the most common 
clinical sign seen in more than 75% of patients, followed by coarse 
skin. 
 
  
 
 
Sl. No. 
 
 
 
 
                      
 
              Signs 
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1 Delayed relaxation of  
ankle jerk 
 
75 
 
77 
 
82 
 
81 
 
84 
 
2 
 
  Coarse skin 
 
62.5 
 
60 
 
80 
 
70 
 
69 
 
3 
 
 Periorbital puffiness 
 
62.5 
 
60 
 
79 
 
70 
 
59 
 
4 
 
 Slow speech 
 
62.5 
 
60 
 
62 
 
65 
 
65 
 
5 
 
 Cold skin 
 
50 
 
50 
 
60 
 
58 
 
55 
 
6 
 
  Bradycardia 
 
37.5 
7.5 
 
46 
 
40 
 
48 
 
50 
 
7 
 
 Slowness of movements 
 
25 
 
36 
 
40 
 
40 
 
34 
 
8 
 
 Facial puffiness 
 
25 
 
25 
 
30 
 
32 
 
32 
 
9 
   
  Goiter 
 
25 
 
26 
 
28 
 
24 
 
28 
 
10 
 
 
  Thick tongue 
 
12.5 
 
13 
 
15 
 
18 
 
16 
 
11 
   
   Hair loss 
 
12.5 
 
10 
 
14 
 
18 
 
13 
 
12 
 
 Limb edema 
 
12.5 
 
10 
 
12 
 
14 
 
10 
  
CONCLUSION 
 
 
  The coexistence of diabetes mellitus with hypothyroidism is a known 
clinical observation. Various meta-analyses done show the prevalence of 
hypothyroidism in general population to be  about 1%. Routine 
screening of thyroid function in diabetics gives a greater yield - 5 to 
15  times than that found in the general population. 
 
  Hypothyroidism in these diabetics may cause subtle symptoms 
especially weight gain and  tiredness,  also  commonly seen  in diabetic  
patients,  and  difficult  to control hyperglycemic state and dyslipidemia. 
 
  In patients having both clinical hypothyroidism and diabetes mellitus, 
diabetes is detected earlier in most patients. 
 
  Increased prevalence of hypothyroidism is seen in female sex, type 1 
diabetics and in elderly type 2 diabetics. 
 
  The  ability  to  diagnose  and  treat  unsuspected  hypothyroidism  in  
diabetic populations  may  result  in  better  control  of  the  diabetic  as  
well  as  of  the dyslipidemic states, thereby greatly enhancing the quality 
of life by preventing premature atheroscelerosis  and Coronary artery 
dieses.  
  This study justifies the view that all diabetic patients should be  
screened for hypothyroidism.           
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PROFORMA 
 
 
Clinical Study of Hypothyroidism in Patients of  
 
Diabetes Mellitus at CMCH, Coimbatore 
  
                                                                                               
 
Case No. 
 
: 
 
OP/IP No. : 
 
Name 
 
: Mr. / Mrs. 
 
Unit : 
 
Age : years DOA : 
 
Sex 
 
: M/F 
 
DOD : 
 
Address 
 
: 
 
Occupation : 
  
 
Income : 
    
Presenting Complaints and History Of Presenting Complaints: 
 
 
      Hypothyroidism Related 
 
          Diabetes Related 
 
General 
 
Gen. Weakness & lethargy 
 Somnolence 
 Cold intolerance 
 Gen. Edema , Wt.gain    
 Periorbital puffiness   
 Hoarseness of voice  
 slowness of speech  
 Swelling in   
 thyroidregion 
 
 Dermatological 
 
Dryness of skin 
Decreased sweating 
Lower limb skin changes & swelling 
Hair loss (head/eyebrow) 
Brittle nails 
Yellowish discoloration of skin 
 
 
General 
 
Polyuria 
Polydipsia 
Polyphagia  
Weight loss 
 
ShortTerm  Complications 
 
 Poor healing of wounds 
Abscess / Carbuncle 
Burning micturition 
Fever (with description) 
Cough 
Nausea , vomiting 
Pain abdomen 
 
Microvascular Complications  
 
Visual  blurring/diplopia/Tingling / 
Numbness/Neuropathic pain  
                                                                                                               
                                                                                              
  
 
                       Gastrointestinal  
                          Constipation  
                          Abd.Distension 
 
                      Cardiorespiratory   
                          Dyspnea  
                          Palpitations 
  
                      Neuromuscular   
                           Paresthesia 
Aches & pains 
Muscle & joint stiffness 
Muscular Cramps 
Physical and/or mental 
slowness 
Depression 
Ataxia 
(cerebellar) 
 
                       Reproductive  
                           Menorrhagia  
                           Infertility  
                           Galactorrhoea  
                           Impotence 
 
Miscellaneous 
 
Giddiness on standing 
Dependant edema (Lower 
limbs/sacral area) 
Abd. bloating/nocturnal diarrhea 
Gustatory sweating 
Impotence 
Puffiness of face 
Swelling of feet / whole body 
Decreased urine output 
Freq. /day; amt. ml/day 
 
Macrovascular complications  
 
Ulceration of skin (non-healing) 
Claudication pain : duration  
                                progression  
Gangrene of limb(s) 
Chestpain / other IHD features 
 
Others 
 
Past History: If already a known 
 
                 
                      Diabetic 
           
           Hypothyroid 
 
• duration 
• how detected 
• type I / II 
• treatment (with duration)
 OAD, Insulin 
• degree of control  
• h/o complications 
 
 
 
 
  Type-Pri. / Sec.  
  
   treatment   
  (withduration) 
 
 
 
 
                                  
 
  
 
 
- h/o pulmonary tuberculosis 
 
- h/o thyroid surgery / radio abalation of thyroid 
 
- h/o drug intake : 
Antithyroiddrugs/Amiodarone/Sertraline/Chloroquine or drugs 
causing inadequate control (Phenobarbitone/Phenytoin/Rmp) 
- Which was diagnosed earlier :  
 
       DM/Hypothyroidism/Simultaneously 
 
: Gap between the two. 
 
 
Personal History: 
 
Diet – Pred. veg/Pred. non-veg- 
 Fiber content of diet: good/low 
Appetite:normal / decreased /increased; 
 Sleep : normal / disturbed (cause) 
Bowel Habits: normal / altered; 
Bladder Habits: normal / altered 
 
Smoking: Beedis / Cigarrettes; 
 
No. / Day; since years 
 
Alcohol: CAGE Questionnaire Score: < 2 / > 2 (total 4)  
 
 
Menstrual History: 
 
Cycles: reg/irregular; duration of cycle days; flow for days; 
 
amt. m1/ flow; clots + / -; pain assoc.; recent change 
 
 
 
 
 
                                                           
  
 
Obstetric History: 
 
H/O infertility + / -;  
Last childbirth (time since)  
No. of pregnancies & outcome 
 
Family History 
(Diabetes,Hypothyroidism)  
Other significant ; Pedigree Analysis 
 
General Physical Examination 
 
1.  Appearance : young/middle aged/elderly; slowness of movements 
 
2.  Built & Nourishment : 
 
3.  Wt.   _   Kg; Ht. cm; BMI = kg/sqm ;US/LS; Hip/Waist Ratio 
 
4.  Hair : Texture – normal/coarse/dry; Hair loss (scalp/outer eyebrow) 
 
5.  Skin : dry & coarse/cold skin/xanthelesma/acanthosis nigrans 
 
: dilated veins over neck/upper thorax 
 
6.  Eyes : Pallor / icterus / periorbital edema 
 
7.  Oral cavity : Tongue; teeth ; mucosa 
 
     :  Hoarseness of voice 
 
8.  Cyanosis / Clubbing (grade) - / nails (Platynychia /  
      Koilonychia/brittle/pallor) 
 
9.  Lymphadenopathy (description) : 
 
10. Oedema : Face/UL/Body/LL/Anasarca; Pitting/non-pitting 
 
 
 
 
 
 
 
 
 
  
Vital Signs: 
 
                               Pulse: rate   / min; rhythm; Volume;  
 
                                    Character: radio-radial / radio-femoral delay 
 
 
                                other pulses felt 
 
    BP:   mm Hg in   limb in   position 
 
                               DiastolicHTN 
 
                               Orthostatic Hypotension (> 20/10 fall on standing for 3 min.) 
 
                               Sustained Handgrip (increased DBP by < 10 mm Hg after 5 min.) 
 Respiration: rate   / min;   
                      abdominal/thoracic/abdominothoracic.  
Body temperature (Axillary): 
     JVP: normal / increased (description) 
 
 
 
Local Examination (Thyroid Region) 
 
Goitre: Present / absent 
 
If present: Grade I / II / III (in neutral position of neck) 
 
: Movement with deglutition 
 
: Tender / non-tender; local temp. Normal/increased 
 
: Shape & size 
 
: Surface – smooth/nodular 
 
: Consistency – soft / firm / hard 
 
: Mobility ; bruit 
 
: Carotid pulsations felt / not felt. 
 
 
 
 
 
 
 
 
 
 
 
  
Systemic Examination 
 
 
                       
                     Cardiovascular System: 
 
Apical Impulse: Localization &  
                           character  
LPH/Epigastric / other pulsation(s)    
Cardiac borders: 
                           pericardialeffusion:  
                             Auscultation:       
 
 
                        Respiratory System: 
                  
                             Droop of  shoulders              
                             Tracheal position       
                              Chest movements 
   Percussion: evidence of pleural effusion 
 
   Auscultation: 
 
 
 
Per Abdomen: 
 
 
   Hepatomegaly / Splenomegaly 
 
   Evidence of ascites 
 
   Bowel sounds: normal / sluggish / absent 
 
 
   
 
 
                                                            
 
 
 
  
 
 
 
Central Nervous System: 
 
Higher Mental Functions: 
Level of consciousness 
Orientation 
                           Memory / Speech & Language / Intelligence 
 
Cranial Nerves: 
 
Optic Fundi 
 
III, IV 
 
Deafness: if present type   ; other cranial N. 
 
Motor System: 
 
Bulk; Tone  
 
Power 
 
Reflexes – Delayed relaxation of Ankle Jerk ;  
Any wasting / motor weakness of Quadriceps  
Sensory System: 
 
Peripheral neuropathy (vibration/joint  position sense/touch/pain) 
 
Others: 
 
Gait: 
 
 
Coordination: normal/RUL/RLL/LUL/LLL 
 
Cerebellar function: 
                             
                         Meningeal irritation signs          
                         Involuntary movements:   
 
 
 
 
 
  
                                        
 
INVESTIGATIONS; 
 
Routine: 
 
Hb   g/dl; TC   /cu-mm; DC :N   % L   %, M   %  E   %, 
B    %, 
ESR   mm/1st hr; Urine: Alb   , Sug   , Microscopy 
 
Blood Urea   mg/dl; Serum creatinine   mg/dl; 
Peripheral Smear: 
CXR 
ECG: 
 
 
Diabetes Related: 
 
 
FPG   mg/dl; PPG   mg/dl; HbA1C (if done)    %;  
Lipid Profile (mg/dl): TGs    ; HDL   ;LDL   ;  
VLDL    X-ray Abdomen (evidence of FCPD): 
 
 
Hypothyroidism Related: 
 
 
Thyroid Profile: TSH   , TT3   , TT4    
Serum Cholesterol: 
 
                            Neck X-ray:  
 
                            Thyroid Ultrasound( if done) 
 
 
 
 
 
 
 
                                                                                                                                                          
 
            
  
 
 
 
 
Others: 
 
- Echocardiography / LFTs / X-ray of involved bones & joints 
 
- Others needed in relation to complication (s) present 
 
Final diagnosis: 
 
I .Treatment 
 
        Drugs                 Dose               Duration 
   
   
 
 
 
II Dietary Advice: 
 
 
 
 
III Problem related to management of either condition in  
           relation to the other 
 
 
 
 
IV Follow Up (when done): 
 
 
 
 
 
SUMMARY OF THE CASE: 
 
 
 
 (  
 
Sl 
No 
Name A 
g 
e 
S 
e 
x 
 
 
FD 
 
 
Gap 
Thyroid Related 
 
T 
Y 
 
D 
 
FPG 
 
PPG 
Complications Rx Symptoms of  Hypothyroidism 
1 2 3 4 5 6 7 8 9 O 
A 
D 
I 
N 
S 
R 
e 
g 
10 11 12 13 14 15 16 17 18 19 20 21 
1. Dovaki 70 F DM 19.66 2 20 166 255    + + +  +  + - IR +      +    +  
2. Ramesh 24 M  . 1 1 90 108          - + R   +      +    
3. Shanti 40 F DM 2.66 2 1 102 128          + - R + + + + + + + - - - + - 
4. Sushila 54 F T 2 2 12 139 164    +  +  +  + - R + + + - - - - + + - - - 
5. Shivraju 21 M T 19.5 1 0.5 80 140          - + R + - - - - - - - - - - - 
6. Devarajan 48 M DT 0 2 2 235 273          + - IR + + + + + + - - - - - - 
7. Govindammal 70 F  . 2 14 80 110    + + +  +  + + IR   +          
8. Kandasamy 50 M DM 0.83 2 0.83 142 230    +    +  + - IR + + + + - - + - - - - - 
9. Anandhi 24 F  . 1 3 104 136          - + R             
10. Annapoorani 49 F  . 2 6 235 281    +  +    + + IR             
11. Parvathy 55 F  . 2 3 160 230 +   +  +  +  + - IR   +          
12. Begum Jaan 70 F  . 2 15 185 211 +   +  +  +  + + IR             
13. Parthasarthy 75 M  . 2 0.5 130 170    +  +  +  + + IR +     +       
14. Rangammal 75 F  . 2 4 134 160    + + + +   + - IR             
15. Vincent 59 M  . 2 4 111 266    +  +    + + IR             
16. Vijaya 28 F  . 1 6 100 149 +   + + +  +  - + IR             
17. Pechiyammal 85 F  . 2 0 176 233          - - .             
18. Kuppayee 75 F  . 2 20 98 132    +  +    + + R   +          
19. Madammal 60 F  . 2 20 234 273 +   +  +    + - IR             
20. Lakshmiammal 70 F  . 2 15 354 412    + + +  +  + - IR             
21. Abida Banu 52 F  . 2 0 199 247     +     - + .   +          
22. Shakuntala 75 F DM 20 2 20 140 188 +   + + +  +  + + IR  +     +      
23. Mylathal 60 F DM 9 2 9 160 210    + + +  +  + + IR             
24. Nazeema 20 F DM 2 1 2 190 260  +        - + IR    +   +    +  
25. Mangalam 34 F  . 1 10 170 230 +   +  +    - + IR             
26. Somashekar 30 M  . 1 8 180 232    +  +    - + IR             
27. Gurumurthy 36 M  . 1 12 380 490    +  +    - + IR             
28. Amnadurai 70 M  . 2 4.5 180 240    +    +  + - IR             
29. Devaraj 50 M  . 2 0.5 160 237        +  + - IR   +      +    
30. Mahadevan 60 M  . 2 2 172 289          + - IR             
31. Mahadevaraj 54 M  . 2 1 180 255          + - IR             
32. Nanjaiah 54 M  . 2 10 190 252    + + +    + + IR             
33. Alexander 70 M  . 2 4 230 280  +  +  +  +  + - IR             
34. Nagaraj 46 M  . 2 2 170 210        +  + - IR       +      
35. Thangamani 78 M  . 2 5 160 190    +  + + + + + - IR             
36. Srinivas 43 M  . 2 0.16 180 212   +     +  + - IR             
37. Rajammal 50 F  . 2 0.83 180 238          + - IR             
38. Madammal 60 F  . 2 1 168 207        +  + - IR             
39. Uma Devi 55 F  . 2 0.5 134 181          + - R       +      
40.    Mariyathal 56 F  . 2 0.5 200 270          + - IR             
41. Fatima 58 F  . 2 13 170 198    + + +  +  + + IR   +          
42. Mary 79 F  . 2 30 210 270  +  + + +  +  + + IR             
43. Gulab Jaan 60 F  . 2 15 170 213    + + +  +  + + IR       +      
 
 
 
 
                                                                                                                                                  
 
 
 
 (  
 
Sl 
No 
Htn 
T N 
FH 
H 
BMI 
M 
Other Systemic S/S Tg 
G 
Ch 
H 
Fu 
U Signs of  Hypothyroidism St 
at 
K 
N 
F 
U 
 
D 
G 
o 
i 
t 
TFTs  
DO C    
C 
V 
S 
R 
S 
P 
A 
C 
N 
S 
   
22 23 24 25 26 27 28 29 30 31 32 33 T3 T4 TSH 
1.         -    SH n 0 - 75 5 10 P + 2 27.81     177 289 + 
2.         -    N .  - 120 7 1.2 . -  17.3     122 154 - 
3. + - - - - - - - - - - - CH fu 2.66 - 186 12.8 1.4 . + 2 35.6     120 143 + 
4. - + + + - - - - + - - - CH k 14 + 106 12.4 1.29 G -  26.17     159 195 + 
5. + - - - - - - - - + - - CH k 20 - 42 2.35 104.6 P -  21.35  PlE A MR 200 204 + 
6. - + + + + + - + - - - - CH k 2 - 53 2.1 34.18 P -  21.8     188 160 + 
7.         -    N . . - 54 6 2.55 . +  25.15     160 125 - 
8. + + + + + + - - - - + - CH n 0 - 50 3.2 31.7 P +  22.95     184 237 - 
9.         -    iS n 0 - 118 8.3 0.21 . -  21.33     140 169 - 
10.         +    N . . + 161 10.17 0.7 . +  27.73     143 190 - 
11.         -    N . . - 160 9 1.4 . +  24.98     180 220 - 
12.         -    N . . - 76 7 1.54 . + 2 21.34     176 250 - 
13.    +    + -    N . . - 87 5.66 5.66 . -  23     130 170 - 
14.         -  +  N . . - 118 6.08 0.5 . +  30.47 LS3 BC   140 180 - 
15.         -    N . . - 145 5.21 6.16 . + 2 19.47     109 177 + 
16.  +      + -    N . . - 143 5.2 1.93 . +  19.95     178 150 - 
17.         -    N . . - 177 5.51 1.02 . - 2 20.5     180 191 + 
18.         -    N . . - 64 5.2 1.52 . -  24     124 170 - 
19.         -    N . . - 82 6.89 1.13 . - 2 12.14     108 120 + 
20.  +    +   -   + N . . - 86 10.82 0.77 . +  30     117 150 - 
21.         -    N . . - 20 8.65 2.72 . -  23   HMA  140 154 - 
22.         - +   SH n 0 - 73 7.11 8.14 . - 2 27.14 LV3 BC   170 220 + 
23.     +    - +   SH n 0 - 78 8.2 9 . +  27     168 207 + 
24.   +    +  -   + SH n 0 - 62 6.24 8.8 . -  22.4     202 180 - 
25.         -    N . . - 70 4.6 0.8 . -  16.84     160 150 - 
26.         -    N . . - 121 7.21 1.53 . -  17.23     162 138 + 
27.         -    N . . - 64 4.5 3.42 . - 1 18.2     148 140 - 
28.  + +      -    N . . - 133 8.14 3.17 . -  24.03     150 210 - 
29.         -  +  N . . - 162 8.2 3.2 . -  24     172 216 - 
30.         -    N . . - 97 4.53 3 . -  25.23     140 182 + 
31.         -    N . . - 103 7.12 1.62 . -  23.2     131 184 - 
32.         -    N . . - 65 4.81 2.74 . - 2 22.24     172 210 - 
33.   +    +  -    N . . - 131 7.93 2.7 . -  27.09     170 176 - 
34.         -    N . . - 150 9.21 12.91 . -  20.05 LV3 BC HMA  133 230 - 
35.         -    N . . - 68 4.73 4 . +  26.23     147 245 - 
36.         -   + N . . - 77 5.23 3.88 . -  25.29     143 288 - 
37.         -    N . . - 140 7.32 4.1 . -  22.01     149 180 + 
38.    +     -    N . . - 143 7 2.88 . -  24.06     150 173 - 
39.         -    N . . - 92 6.3 3 . -  27 LV3    140 253 - 
40.         -    N . . - 117 6.72 1.98 . +  22.34     191 200 - 
41.         -    N . . - 113 6.8 3.42 . -  21.29 LV3    190 192 + 
42.         -    N . . - 89 7.68 2.16 . - 2 17.05   A  138 262 - 
43.         -    N . . - 95 6.17 2.34 . - 2 23.07     131 206 + 
 
 
 
 (  
 
44. Kuruvammal 68 F DM 13 2 18 147 184 +   +  +  +  + + IR + + - - - - - - - - - - 
45. Gafoor 60 M DM 7 2 7 150 210    + + +  +  + - IR   +    +      
46. Siddayan 75 M DM 20 2 20 180 230  +  + + +  +  + + IR             
47. Madayan 50 M DM 5 2 5 138 160        +  + - R             
48. Kumarswamy 48 M  . 2 4 142 180   + + + +  +  + - IR             
49. Laxmi 38 F  . 1 16 180 250    +      - + IR             
50. Papammal 22 M DM 3 1 3 130 190          - + R             
51. Krishnaraj 58 M  . 2 10 160 230    +  +  +  + + IR             
52. Nagaraj 43 M  . 2 3 170 230    +      + + IR             
53. Sankaran 40 M  . 2 2 110 170          + - R             
54. Gurumurthy 20 M  . 1 1 140 190          - + IR             
55. Dhandapani 45 M  . 2 5 136 164          + - R             
56. Krishna 42 M  . 2 2 160 198    +    +  + - IR             
57. Lawrence 30 M DM 8 1 8 130 180 + + + + + +    - + R +      + +     
58. Sivaraj 55 M  . 2 10 190 240    +  +  +  + + IR + +   +        
59. Sivaraman 55 M DM 9 2 9 188 230    + + +  +  + - IR +            
60. Hanif 49 M  . 2 7 210 270    +    +  - - IR             
61. Rajashekar 40 M  . 2 2 138 174          - - R             
62. Mutaiah 60 M  . 2 12 130 250   + +  +  +  + + IR             
63. Narayan 60 M  . 2 16 132 250    +  +  +  + + IR             
64. Raju 30 M  . 1 10 270 350 + + + + + +    - + IR             
65. Madhu 49 M  . 2 2 180 230        +  + - IR + +     +     + 
66. Govinda 68 M  . 2 17 140 182   + + + +  +  + - R             
67. Krishna 63 M  . 2 10 150 230    +    +  + + IR             
68. Raja 30 M  . 1 12 140 190 + +    +    - + R             
69. Mohan 55 M  . 2 8 117 264    +    +  + - R             
70. Krishna 82 M  . 2 3 104 150 +   +    +  + - R             
71. Ameer 60 M  . 2 6 190 230    + + +  +  + + IR             
72. Nanjappan 50 M  . 2 7 210 290    + + + +   + - IR             
73. Veerasamy 70 M  . 2 15 210 230    +    +  + + IR     +     +  + 
74. Shahabudeen 42 M  . 2 4 146 184          + - R             
75. Manoharan 70 M  . 2 13 140 180    +    +  + + R             
76. Satish 34 M  . 1 10 190 240    +  +  +  - + IR +            
77. Rajgopal 66 M  . 2 12 116 173    + + +  +  + + R +            
78. Venkatesh 50 M  . 2 8 180 210    +  +  +  + - IR +      +      
79. Senniyappan 52 M  . 2 6 130 170    +    +  + - IR             
80. Rangasamy 62 M  . 2 10 110 130    +    +  + + R             
81. Raju 20 M  . 1 0.5 128 142          - + R             
82. Surendran 50 M  . 2 4 139 179  +  + + +  +  + - IR             
83. Subbaiah 60 M  . 2 11 130 148    +    +  + - R             
84. Mahalingam 68 M  . 2 14 160 204    +    +  + + IR   +       +   
85. Lingaraju 26 M  . 1 2 190 210          - + R             
86. Krishna 38 M  . 1 16 250 270  +  + + +  +  - + IR             
87. Ayyadurai 79 M  . 2 23 132 178    +    + + + + R             
88. Venkatesh 50 M  . 2 7 154 209   + +  +  +  - - IR             
89. Aziz Khan 70 M  . 2 15 136 172    +  +  +  + - R     +        
90. Selvaraju 50 M  . 2 8 170 230    + + +  +  + + IR             
91. Muniyandi 50 M  . 2 10 130 180          + - R             
 
 
 
 (  
 
 
44. + + + + + + + - + - - - CH k 5 + 30 3.01 25 P + 2 25     174 238 + 
45.       +  -    SH n 0 - 64 5 8 . +  25     138 220 + 
46.         -    SH n 0 - 70 6 7.04 . -  24.8     148 210 + 
47. - - - - - - - - + - - - SH n 0 + 80 7.04 7.62 . -  23.2     158 208 + 
48.        + -    N . . - 92 9 2.06 . -  21     170 204 - 
49.         -    N . . - 98 6 2.5 . +  23     200 234 - 
50.         -    SH n 0 - 40 3.8 6.8 . -  19     210 230 + 
51.         -    N . . - . . 3.02 . +  24     204 219 + 
52.         -    N . . - 102 7 1.5 . + 2 23.28     230 202 + 
53.  +       -    N . . - . . 2 . -  23   A  190 170 + 
54.      +   -  +  N . . - . . 3.07 . -  21     207 140 - 
55.         -    N . . - . . 2.81 . -  22.04     170 168 - 
56.         -    N . . - 78 5.6 2.19 . - 2 22.24   HMA  209 170 + 
57.    +   +  -    SH n 0 - 70 5 7.48 . -  19.06  PT   180 184 + 
58.         -    N . . - . . 3 . -  24.12     230 210 - 
59.    +     -    SH n 0 - 78 6.02 9.02 . +  28     270 220 + 
60.      +   -    N . . - 90 5 2.07 . + 2 19.24     320 182 + 
61.         -    N . . - . . 0.9 . -  21.32     174 185 - 
62.         -    N . . - . . 0.8 . -  23.23     176 209 - 
63.         - +   N . . - 100 6 1.28 . +  21.47     202 168 - 
64.   +      -    N . . - 87 5.98 1.88 . -  19.24     260 170 + 
65.         -    N . . - . . 1.5 . -  22     210 209 - 
66.         -    N . . - . . 1 . - 2 24.1     194 170 - 
67.         -   + N . . - . . 2.5 . -  23     200 202 - 
68.         -    N . . - 104 6 2.54 . -  19     210 140 + 
69.         -    N . . - . . 1 . -  21.19 PE    170 172 + 
70.    +    + -    N . . - . . 1.76 . -  22     220 230 - 
71.         -    N . . - . . 1.25 . -  23.07     119 210 - 
72.         -    N . . - . . 3.2 . +  25.19     232 260 + 
73.         -    N . . - 103 5.15 3 . -  24.2     194 263 - 
74.         -    N . . - . . 1.43 . + 2 22.1     170 194 + 
75.         -    N . . - . . 1.24 . -  23.15     170 200 - 
76.  +    +   -  +  N . . - . . 1.93 . -  18.74     194 153 - 
77.         -    N . . - 109 6.1 3 . -  24.2     160 172 - 
78.         -    N . . - . . 1.28 . +  22.02     184 179 - 
79.         -    N . . - . . 2.51 . -  23.23     220 241 - 
80.         -    N . . - . . 3.5 . +  23     230 231 - 
81.  +      + -    N . . - . . 4 . - 1 20.3     241 239 - 
82.         -   + N . . - 85 7.23 1.07 . -  27     300 210 + 
83.         -    N . . - . . 1.46 . - 2 24.2     170 190 - 
84.         -    N . . - . . 3.04 . +  23.09     232 210 + 
85.        + -    N . . - . . 1.29 . -  19.11     190 150 - 
86.   +  +    -    N . . - . . 2.23 . -  20.04     270 178 + 
87.         -    N . . - . . 2.47 . -  24.6     199 110 - 
88.   +   +   -    N . . - . . 2.9 . -  22.04     210 170 - 
89.         -    N . . - . . 1.9 . -  21  LA   160 210 + 
90.         -    N . . - . . 2.05 . +  23.97     140 202 + 
91.         -    N . . - 112 5.7 4.5 . +  25.83     158 178 - 
 
 
 
 
 
 (  
 
92. Rangan 65 M  . 2 17 116 150    +  +  +  + - R             
93. Cheran 25 M  . 1 7 140 190 +         - + R   +    +      
94. Rallikumar 36 M  . 1 13 180 243    + + +  +  - + IR             
95. Prakash 50 M  . 2 7 140 162        +  + - R             
96. Iqbal 58 M  . 2 8 150 199    + + +  +  + - IR +            
97. Chennaiah 25 M  . 1 7 130 171          - + R             
98. Narayana 43 M  . 2 2 130 164          + - R             
99. Shankar 30 M  . 1 10 170 238    +  +    - + IR +      +      
100. Kemagaraj 55 M  . 2 4 118 169    +      + - R             
101. Sidayan 78 M  . 2 18 139 163    + + +  +  + + R             
102. Madan 35 M  . 1 14 174 221 + +  + + +    - + IR             
103. Nageraj 20 M  . 1 2 190 220 +         - + R             
104. Gurumurthy 56 M  . 2 1 188 213    +  +  +  + - IR    +         
105. Siddique 80 M  . 2 23 144 180    +  +  +  + + R             
106. Rehmat 55 M  . 2 1 149 169        +  + - R             
107. Veppammal 55 F  . 2 10 150 202    +    +  + + IR             
108. Puttammal 50 F  . 2 0.5 116 140      +  +  + - R             
109. Saroja 56 F  . 2 3 163 238    +      + - IR    +      +   
110. Gayathri 44 F  . 2 2 190 232    + +  + +  + + IR             
111. Jaleena B 36 F  . 2 1 140 170          + - R             
112. Salima B 65 F  . 2 15 178 213 +   + + +  +  + + IR             
113. Sadayammal 70 F DM 22 2 20 180 220    + + +  +  + + IR + + + - + + + + + + - - 
114. Bharathi 23 F  . 1 7 190 290  +  +      - + IR             
115. Kumari 35 F DM 10 1 10 250 370   + +  +    - + IR + +     +    +  
116. Meenaxi 20 F  . 1 1 170 200          - + R             
117. Parvathy 50 F  . 2 2 138 268        +  + - R             
118. Roopa 26 F  . 1 4 160 220 +   +      - + IR   +       +   
119. Kamagammal 
 
58 F  . 2 3 180 240    +      + - IR             
120. Farida 34 F DM 9 1 11 350 470  +  +  +    - + IR + - - + + + - - - - - + 
121. Ayesha 22 F  . 1 4 330 500   + +  +    - + IR             
122. Savitri 23 F  . 1 3 138 180          - + R             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (  
 
92.         -    N . . - . . 1.13 . -  22.38     170 200 - 
93.      +   -    N . . - . . 1.75 . - 1 20.22     120 128 - 
94.    +     -    N . . - 107 4.87 4.07 . +  24.9     190 230 + 
95.         -  +  N . . - . . 1.07 . -  22     180 154 - 
96.         -    N . . - . . 3.2 . -  19.87     152 180 - 
97.         -    N . . - 120 5 2.3 . -  19.01     198 176 + 
98.         -  +  N . . - . . 3.17 . +  27     153 150 - 
99.  +      + -    N . . - . . 1.23 . -  18.43     179 188 - 
100.         -    N . . - . . 3.21 . -  21.05     169 220 - 
101.         -    N . . - . . 1.32 . + 2 24     250 110 - 
102.         -    N . . - 92 5.07 1.92 . -  17.05  PT   117 163 + 
103.    +    + -    N . . - . . 3.1 . -  17.64     230 184 - 
104.         -    N . . - 132 5.23 2.12 . -  23.02     167 189 + 
105.         -   + N . . - . . 1.99 . - 2 19.98     119 220 - 
106.         -    N . . - . . 2.04 . +  22.84     123 168 - 
107.   +      -    N . . - 109 7.03 5.01 . -  22.74     180 250 + 
108.         -  +  N . . - . . 4.22 . -  23     118 241 - 
109.   +    +  -    N . . - . . 1.47 . . 2 21.22     176 200 + 
110.         -  +  N . . - 160 7 2.19 . .  22.43     177 270 + 
111.         -    N . . - . . 3.51 . +  23     177 238 - 
112.         -    N . . - . . 1.42 . -  21.74     174 198 + 
113. + + + + + + - + - - - + CH fu 2 - 60 4.8 6.01 P -  24     180 234 + 
114.         -    N . . - . . 0.54 . -  18     142 170 + 
115.  +   +  +  -    SH n 0 - 88 7 6.42 . -  16.99     188 152 + 
116.         -  +  N . . - . . 1 . -  17.53     190 150 + 
117.       +  -    N . . - 106 5.4 0.69 . -  23.2     163 230 - 
118.         -   + N . . - . . 1.52 . - 1 19.04     220 162 + 
119.         -    N . . - 95 5.65 0.87 . +  24     290 250 - 
120. + - - - - - - - - - - - CH k 2 - 30 2.1 15.88 G -  18.58     250 142 + 
121.         -    N . . - . . 1.72 . -  18.94     190 170 - 
122.   +      -    N . . - . . 1.68 . -  17.5     290 138 - 
 
 
 
KEY TO THE MASTER CHART 
 
H.No. = Hospital in/out-patient Number 
M = Male 
F = Female 
FD = First Detected of Diabetes and Hypothyroidism 
DM = Diabetes mellitus 
T = Thyroid Dysfunction 
Gap = Gap between detection of Diabetes and Hypothyroidism 
TY = Type of Diabetes mellitus (1 = type 1 / 2 = type 2 )  
D = Duration 
FPG = Fasting Plasma Glucose (mg/dl) 
PPG = Postprandial Plasma Glucose (mg/dl)  
A1c = Glycated Hemoglobin (%) 
1 = Hypoglycemia 
2 = Diabetic Ketoacidosis 
3 = Hyperglycemic Hyperosmolar State 
4 = Neuropathy 
5 = Nephropathy 
 
6 = Diabetic Retinopathy 
7 = Cerebrovascular Accident 
8 = Ischemic Heart Disease 
9 = Peripheral Vascular Disease 
Rx = Treatment 
OAD = Oral Antidiabetics 
INS = Insulin 
Reg = Regularity of Treatment (IR = Irregular / R = Regular) 
10=Generalised Weakness & lethargy 
11=Dryness of skin 
12= Cold intolerance 
13 =Decreased sweating 
14 =Weight gain 
15 =Paraesthesia 
16 =Constipation 
17 =Hoarseness of voice 
18 =Anorexia 
19 =Decreased hearing 
20 =Menorrhagia 
 
21 =Palpitations 
22 =Delayed relaxation of ankle jerk 
23 =Coarse skin 
24 =Periorbital puffiness 
25 =Slow speech 
26 =Cold skin 
27 =Bradycardia 
28 =Slowness of movements 
29= Facial puffiness 
30 =Goiter 
31 =Thick tongue 
32 =Hair loss 
33 =Limb edema 
Stat = Status 
SH = Subclinical Hypothyroidism 
CH = Clinical Hypothyroidism 
iS = Subclinical Hyperthyroidism 
N = Normal 
KNFU = Known (k) / Newly Detected (n) / Follow up (fu)  
TFTs = Thyroid Function Tests 
T3 = Triiodothyronine 
T4 = Thyroxine 
TSH = Thyroid Stimulating Hormone 
AMA = Anti-Microsomal Antibody 
FNAC = Fine Needle Aspiration Cytology 
 
                                                  CONSENT FORM 
Yourself  Mr/Mrs/Ms  _________________ are  being asked to be a participant in 
the study titled – “Clinical study of Hypothyroidism in patients of Diabetes 
Mellitus” in CMC Hospital, conducted by Dr.T.A.Naufal Rizwan, Post Graduate 
student, Department of General Medicine,Coimbatore Medical College. You are 
eligible after looking into the inclusion  criteria. You can ask any questions      
before agreeing to participate. 
  Purpose of the research  
  To do the clinical study of Hypothyroidism in patients of Diabetes Mellitus and  
to study the patients having both endocrine disorders and their thyroid 
function  status,  in relation to  the  age  and  sex,  the  type  of diabetes , age  at  
detection of either condition and the clinical features. 
Procedures involved  
    This research is intended to do a study of hypothyroidism , by means of  thyroid  
 
 function tests, in  patients of  diabetes mellitus, either previously or newly  
 
   diagnosed, and aged more  than 19 years. 
 
 
 
 
 
    
 Decline from participation  
You have the option to decline from participation in the study without any 
discrimination and you will be treated as per the existing protocol for your 
condition. 
Privacy and confidentiality  
Privacy of  the individual will be respected and any information about you or  
provided by you during the study will be kept strictly confidential. 
Authorization publish results  
Results of the study may be published for scientific purposes and / or  
presented to scientific groups; however you will not be identified. 
  
Statement of Consent   
I volunteer and consent to participate in this study. I have read the consent or it has 
been read to me. The study has been fully explained to me and I may ask questions 
at any time.  
________________________________           _______________  
Signature of Left Hand thumb Impression         Date  
(Volunteer Subject)       
______________________________   ________________  
Signature (Witness)      Date  
 
 
LIST OF ABBREVIATIONS USED 
 
 
AMA= Anti-Microsomal Antibody 
ASH= Asymmetrical Septal Hypertrophy 
AT =Autoimmune Thyroiditis  
BMI = Body Mass Index (kg/m
2
)  
BP= Blood Pressure 
CABG=Coronary Artery Bypass Graft  
CAD= Coronary Artery Disease  
CCF=Congestive Cardiac Failure 
CH= Clinical Hypothyroidism 
CLIA= Chemiluminescence Immunoassay 
DBP=Diastolic Blood Pressure 
DIT= Di-iodotyrosine 
DKA= Diabetic Ketoacidosis 
DM=Diabetes Mellitus 
DR= Diabetic Retinopathy  
DUB=Dysfunctional Uterine Bleeding  
EIA= Enzyme Iimmunoassay  
FCPD=Fibrocalcific Pancretic Disease  
FPG = Fasting Plasma Glucose (mg/dl)  
F= Female 
FNAC= Fine Needle Aspiration Cytology 
FT3=Free triiodothyronine 
FT4 =Free Thyroxine 
FT4I= Free Thyroxine Index  
GCT=Glucose Challenge Test  
HbA1c= Glycated 
Haemoglobin 
HHS= Hyperglycemic Hyperosmolar State 
HTN=Hypertension 
IDDM=Insulin Dependent Diabetes Mellitus 
IFG=Impaired Fasting Glycaemia  
IGT=Impaired Glucose Tolerance  
IHD= Ischemic Heart Disease  
LDL=Low Density Lipoprotein  
LPH=Left Parasternal Heave  
M=Male 
MIT= Mono-iodotyrosine 
MODY=Maturity Onset Diabetes of Young  
NIDDM=Non- Insulin Dependent Diabetes Mellitus  
NS=Not Significant 
OAD=Oral antidiabetic drugs 
PPG = Postprandial Plasma Glucose (mg/dl) 
rT3=reverse Triiodothyronine  
RAIU= Radioactive Iodine Uptake  
RT3U=T3 Resin uptake  
SH=Subclinical Hypothyroidism  
S=Significant 
T3= Triiodothyronine 
T4 =Thyroxine 
TBG= Thyroxine Binding Globulin 
TBPA= Thyroxine Binding Prealbumin or Transthyretin 
TD= Thyroid Disease 
TFT= Thyroid Function Tests  
Tg = Thyroglobulin  
TGs=Triglycerides 
TPO= Thyroid peroxidase 
TRH=Thyrotropin 
TSH=Thyroid Stimulating Hormone  
TSHRAb= TSH receptor antibody  
